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Cardiovascular diseases are the major causes of morbidity and mortality in industrialized 
countries. Adult cardiomyocytes are terminally differentiated, and thus unable to proliferate 
and replace degenerated tissue in case of an injury. The heart is one of the least regenerative 
organs and a significant loss of cardiomyocytes can result in irreversible, congestive heart 
failure. 
Cardiovascular regenerative medicine aims to develop strategies for producing 
functional myocardial tissue to be used in cell replacement therapy. The most promising cell 
types for this are human embryonic stem cells (hESCs) and induced pluripotent stem cells 
(hiPSCs). They are able to differentiate into any cell type in body and proliferate indefinitely 
in undifferentiated state, making them a good source for cardiomyocytes (CM). HESCs are 
isolated from the inner cell mass of donor blastocyst stage embryos and iPSCs are generated 
from somatic cells by reprogramming them into pluripotent, embryonic stem cell-like state. 
Several methods have been developed to differentiate PSCs into cardiomyocytes. The 
differentiation efficiency varies between currently used differentiation assays, and none of 
them has been able to produce pure cardiomyocyte populations. Pure populations are essential 
for regenerative medicine, as other cell types or undifferentiated stem cells might cause 
serious problems when transplanted into human. Also the maturation stage of the generated 
cardiomyocytes is a problem, as they resemble more of the embryonic or fetal type, which 
have some structural and functional differences compared to adult cardiomyocytes. 
The aim of our study was to generate functional CMs from different lines of 
human pluripotent stem cells using spontaneous EB differentiation assay, and to find a 
purification method that doesn’t affect cell viability. We used two hESC –lines (HS346; 
HS181) and one iPSC –line (UEFhfiPS 1.4). Different cell lines were used to study their 
influence on the CM differentiation, as the success is often cell line dependent. All cell lines 
produced clusters of beating CMs, but UEFhfiPS 1.4 -line produced clearly more of them than 
either of the hESC –lines. On average, first contracting areas appeared on UEFhfiPS 1.4 cell 
line on day 14 after the start of differentiation protocol. Contracting areas varied in shape, size 
and beating rate, and were usually seen on only few wells on each differentiation batch. After 
microdissection, beating areas were dissociated to single cells using collagenase-pancreatin-
solution that was found to have no visible effect on cell viability. 
The successful differentiation to cardiomyocytes was shown by the expression 
of cardiac genes (MYL-2, GATA4, ANF, Nkx2.5) using RT-PCR. Immunolabelling with 
myosin heavy chain (MHC) showed clear sarcomeric structures typical for cardiomyocytes. 
Although the amount of the generated CMs was small, the results show that spontaneous EB 
method is usable for creating functional CMs for small scale studies. 
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Ihmisen monikykyinen kantasolu, erilaistaminen, sydänlihassolu 
Sydän- ja verisuonisairaudet ovat suurimpia kuolleisuuteen ja sairastavuuteen vaikuttavia 
tekijöitä teollistuneissa maissa. Aikuiset sydänlihassolut ovat lopullisesti erilaistuneita, ja 
tämän vuoksi ne eivät pysty jakaantumaan ja korvaamaan tuhoutunutta kudosta vaurion 
yhteydessä. Sydän on yksi vähiten uudistuvista elimistä, joten merkittävä sydänlihassolujen 
kato voi johtaa palautumattomaan sydämen vajaatoimintaan.  
Sydän- ja verisuonisairauksiin erikoistuneen regeneratiivisen lääketieteen 
tarkoituksena on kehittää erilaisia menetelmiä, joilla saadaan tuotettua toimivaa 
sydänlihaskudosta tuhoutuneen tilalle. Lupaavimpia solutyyppejä tähän tarkoitukseen ovat 
ihmisalkion kantasolut (hESC) ja indusoidut monikykyiset kantasolut (hiPSC). Nämä 
solutyypit pystyvät erilaistumaan miksi tahansa elimistön solutyypiksi ja jakautumaan 
rajattomasti erilaistumattomassa muodossa, mikä tekee niistä hyvän sydänlihassolujen 
lähteen. Ihmisalkion kantasolut eristetään alkiorakkulavaiheessa olevien alkioiden 
sisäsolumassasta ja indusoidut monikykyiset kantasolut tuotetaan somaattisista soluista 
uudelleenohjelmoimalla ne kantasolumaiseen tilaan. Sydänlihassoluja tuottavien 
erilaistamismenetelmien tehokkuus vaihtelee, eikä millään menetelmällä ole vielä pystytty 
tuottamaan täysin puhtaita viljelmiä. Puhtaat, ainoastaan sydänlihassoluja sisältävät  
populaatiot ovat kumminkin välttämättömiä solukorvaushoidoissa, sillä muut solutyypit tai 
erilaistumattomat kantasolut voivat aiheuttaa vakavia ongelmia joutuessaan elimistöön. 
Ongelmia aiheuttaa myös se, että erilaistetut sydänlihassolut muistuttavat enemmän aikaisien 
kehitysasteiden sydänlihassoluja, joiden toiminnassa ja rakenteessa on eroja aikuisiin soluihin 
verrattuna. 
Tutkimuksemme tarkoitus oli tuottaa toimivia sydänlihassoluja ihmisen 
monikykyisistä kantasolulinjoista spontaania embryoidikappaleen (EB) 
muodostumismenetelmää käyttäen sekä löytää solujen erotusmenetelmä, joka ei vaikuta 
niiden elinkykyisyyteen. Käytimme kahta ihmisalkion kantasolulinjaa (HS346; HS181) ja 
yhtä indusoitua kantasolulinjaa (UEFhfiPS 1.4). Valitsimme eri kantasolulinjoja, sillä 
erilaistumisen onnistuminen on usein solulinjariippuvaista. Kaikki solulinjat tuottivat 
kardiomyosyyttejä, mutta UEFhfiPS 1.4 –kantasolulinja selkeästi eniten. Ensimmäiset 
sykkivät solut ilmestyivät UEFhfiPS 1.4 –linjalla keskimäärin 14 päivää erilaistamisen 
aloittamisesta. Sykkivät alueet olivat eri muotoisia ja eri kokoisia. Lisäksi ne sykkivät eri 
frekvensseillä ja ilmestyivät yleensä vain muutamille maljoille kussakin erilaistamiserässä. 
Sykkivien alueiden leikkaamisen jälkeen ne hajotettiin kollagenaasi-pankreatiini –liuoksella, 
joka ei silmämääräisesti vaikuttanut solujen elinkykyisyyteen ja solut jatkoivat sykkimistä 
maljauksen jälkeen. Erilaistamisen onnistuminen selvitettiin sydängeenien (MYL-2, GATA4, 
ANF, Nkx2.5) ilmenemisellä käyttäen kvantitatiivista RT-PCR:ää. Myosiinin raskasketjun 
(MHC) vasta-ainevärjäys osoitti kardiomyosyyteille ominaiset selkeät sarkomeeri rakenteet. 
Sydängeenien määrät olivat koholla verrokkinäytteisiin nähden ja MHC-värjäys paljasti 
selkeät sarkomeerirakenteet osoittaen, että sykkivät solut olivat sydänlihassoluja. Vaikka 
tuotettujen sydänlihassolujen määrä oli pieni, käyttämämme menetelmä soveltuu toimivien 
sydänlihassolujen erilaistamiseen pienimuotoisia tutkimuksia varten. 
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ABBREVIATIONS 
 
ALCAM Activated leukocyte cell adhesion molecule 
ANF Atrial natriuretic factor 
AP Action potential 
bFGF Basic fibroblast growth factor 
BIO 6-bromoindirubin-3´-oxime 
BMP Bone morphogenic protein 
BMP Bone morphogenic protein 
C-KIT Proto-oncogene, type 3 transmembrane receptor for MGF 
CK-MB  Creatine kinase-MB (M, muscle; B, brain) 
CM Cardiomyocyte 
c-Myc Avian myelocytomatosis viral oncogene homolog 
cTnT Cardiac troponin T 
cTnI Cardiac troponin I 
DKK1 Dickkopf homolog 1 
EB Embryoid body 
eGFP Enhanced green fluorescence protein 
END-2 Visceral endoderm –like cell line 
FACS Fluorescence activated cell sorting 
Flk1 Fetal liver kinase 1, also known as KDR 
GATA4 Zinc finger transcription factor 4 
GSK3 Glycogen synthase kinase 3 
hESC Human embryonic stem cell 
hiPSC Human induced pluripotent stem cell 
hPSC Human pluripotent stem cell 
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HSVtk/GCV Herpex simplex virus thymidine kinase/ganciclovir 
Isl-1 LIM homeodomain transcription factor 1 
ITGA1 Integrin alpha 1 
KDR Kinase insert domain-containing receptor, also known as Flk-1 
Klf4 Kruppel-like factor 4 
Lin28 Lin-28 homolog 
MACS Magnetic-assistent cell separation 
MEF2C  Myocyte enhancer factor 
mESC Mouse embryonic stem cells 
MGF Mast cell growth factor, also known as stem cell factor 
MHC Myosin heavy chain 
MLC Myosin light chain 
MLC2a Myosin light chain (atrial) 
MLC2v Myosin light chain (ventricular) 
MYH6 α-myosin heavy chain; α-MHC 
MYL2 Ventricular myosin light chain 
Nanog Nanog homeobox 
Nkx2.5 Nk2 transcription factor related locus 5 
Oct3/4 Octamer-binding transcription factor 3/4 
PDGFR-α Platelet-derived growth factor receptor-α 
PDGFRB Platelet-derived growth factor receptor, beta polypeptide 
PECAM1 Platelet endothelial cell adhesion molecule 1  
PGI2 Prostaglandin I2 
PSC Pluripotent stem cell 
p38MAPK P38 mitogen activated protein kinase 
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RT-PCR Reverse transcription-polymerase chain reaction 
SIRPA Signal regulatory protein α 
SRF Serum response factor 
SOX2 SRY (sex determining region Y)-box 2 
SSEA-1 Stage-spesific embryonic antigen-1 
SSEA-4 Stage-specific embryonic antigen-4 
Tbx5 T box protein 5 
Tbx5/Tbx20 T box protein 5/20 
TGF-β Transforming growth factor β 
THY1 Thy-1 cell surface antigen 
TMRM Tetramethylrhodamine methyl ester perchlorate 
TRA 1-60 TRA-1-60-antigen 
TRA-1-81 TRA-1-81-antigen 
VCAM1 Vascular cell adhesion molecule 1 
VEGF Vascular endothelial growth factor 
 
Wnt Wingless/Int –protein family 
Wnt Wingless-type MMTV (mouse mammary tumor virus) integration site family 
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1 INTRODUCTION 
Cardiovascular diseases are the major causes of morbidity and mortality in industrialized 
countries (Egashira et al. 2011). The heart is one of the least regenerative organs as adult 
cardiomyocytes are terminally differentiated, and thus unable to proliferate and replace 
degenerated tissue in case of an injury (Norström et al. 2006, Filipczyk et al. 2007). 
Pathological processes (e.g. ischemia, viral infection, cardiomyopathies) that cause significant 
loss of cardiomyocytes lead to decreased heart function, loss of contractile function and can 
result in irreversible, congestive heart failure (Habib et al. 2008, Mignone et al. 2010). Heart 
does have resident cardiac stem cells which give it a limited capacity for myocardial 
regeneration, but they cannot restore heart function after ischemia or other significant injury 
(Vidarsson et al. 2010, Mercola et al. 2011). Currently, heart transplantation is the only 
effective long-term treatment available for heart failure patients, even though it is limited by 
shortage of donor organs, cost and immunological rejection (Goh et al. 2005, Mignone et al. 
2010). There are also various types of surgical treatments, (e.g. ventricular assist device 
implantation) but they are applicable for only limited number of patients (Goh et al. 2005, 
Yoshida and Yamanaka 2011) Medical treatment for heart failure improves heart function by 
adjusting the preload, afterload and contractility, but the efficacy varies between patients, and 
discontinuation will deteriorate heart function (Mignone et al. 2010, Yoshida and Yamanaka 
2011). Although current therapies available for heart failure patients improve cardiac 
function, quality of life and survival, the lack of restorative treatments makes chronic heart 
diseases one of the most important targets for novel therapies, especially for regenerative 
medicine (Shiba et al. 2009, Egashira et al. 2011). 
Cardiovascular regenerative medicine aims to develop strategies for generating functional 
myocardial tissue to be used in cell replacement therapy or mobilize heart’s endogenous stem 
and progenitor cells for regeneration (Habib et al. 2008, Dambrot et al. 2011). The goal is to 
replace scar tissue and nonfunctional cardiomyocytes with new cells that engraft, survive, 
mature and integrate well with the host myocardium, improving cardiac function and 
relieving the symptoms of cardiac failure. Hence, identification of cells that have the potential 
to differentiate into cardiomyocytes or mobilize endogenous stem and progenitor cells is 
required for successful cell replacement therapy (Mignone et al. 2010, Yoshida and 
Yamanaka 2011). 
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Use of several cell types as a source for regenerative heart medicine has been investigated. 
These include endothelial progenitor cells from blood and bone marrow, cardiac progenitor 
cells, mesenchymal stem cells from bone marrow and other tissues, human embryonic stem 
cells and induced pluripotent stem cells (Shiba et al 2009, Vidarsson et al 2010, Yamashita 
2010). First cell therapy attempts were made delivering bone marrow cells to infarcted mouse 
hearts (Orlic et al. 2001, Jackson et al. 2001, Dambrot et al. 2011). Even though short-term 
improvement in cardiac contractile and relaxation function was seen, it was later discovered 
that the engrafted cells did not transform and generate significant amounts of new 
myocardium (Murry et al. 2004, Dambrot et al. 2011, Thorrez and Sampaolesi 2011). It has 
been suggested that the transplanted cells improved cardiac function through enhanced 
angiogenesis and thus better blood supply to the damaged area (Habib et al. 2008, Dambrot et 
al. 2011). Also elevated endogenous repair mechanisms and undiscovered paracrine factors 
have been suggested to be the possible underlying mechanisms, because they might favorably 
influence post-infarct remodeling or promote collateral formation (Habib et al. 2008, 
Mignone et al. 2010, Dambrot et al. 2011). Because of limited long-term benefits on cardiac 
function and inconclusive data from adult stem cell therapy trials, focus has been turned to 
groups of cells that actually have the potential to remuscularize damaged heart.  
The most promising cell types for this are human embryonic stem cells (hESCs) and induced 
pluripotent stem cells (hiPSCs) (Shiba et al. 2009, Dambrot et al. 2011). These cell types are 
able to differentiate into any cell type in body and proliferate indefinitely in undifferentiated 
state, making them a good source for cardiomyocytes and cardiac progenitor cells for cell 
therapy or in vitro drug screening and toxicology -models. Human iPSC-derived 
cardiomyocytes could also be used as human disease models, for instance, inheritable diseases 
associated with gene mutations (e.g. cardiac channelopathies, cardiomyopathies) (Dambrot et 
al. 2011, Kattman et al. 2011a). In order to have sufficient amount and pure cardiac 
progenitors and CMs from PSCs, defining the pathways that control cardiac differentiation is 
important. Some of these pathways and growth factors have been discovered (Rajala et al. 
2011, Willems et al. 2011). Even though the understanding of the factors that drive the 
differentiation to cardiac fate is incomplete, hESCs and hiPSCs have been successfully 
differentiated into cardiomyocytes using various methods (Vidarsson et al. 2010, Rajala et al. 
2011). Despite the achievements in developing cardiomyocyte differentiation protocols, they 
still remain uncontrolled and inefficient, differentiation rate varying from 1% to ~50% of the 
total cells (Norström et al. 2006, Sun et al. 2010, Dambrot et al. 2011, Rajala et al. 2011). 
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Novel efficient and cost-effective cardiomyocyte differentiation methods have to be designed 
and optimized and existing protocols have to be improved if the target is cell therapy for 
myocardial infarction as it may need up to 1 billion new cardiomyocytes to replace the 
damaged area (Filipczyk et al. 2007, Habib et al. 2008, Vidarsson et al. 2010, Narsinh et al. 
2011). It has been noticed that human stem cell derived cardiomyocyte populations consist of 
mixtures of different cardiac cell types, including atrial, nodal, ventricular and pacemaker 
cells in various different developmental stages. This makes developing efficient, large-scale 
methods for enriching and selecting cardiomyocytes from other cell types important 
(Norström et al. 2006, Habib et al. 2008, Rajala et al. 2011). Maturation of cardiomyocytes 
presents another problem; stem cell derived cardiomyocytes usually resemble embryonic or 
fetal cardiomyocytes which have some structural and functional differences compared to adult 
cardiomyocytes (Filipczyk et al. 2007, Narsinh et al. 2011, Rajala et al. 2011). Thus in vitro 
methods that enable higher degree of maturation has to be designed (Vidarsson et al. 2010). 
Cardiac clusters might also contain undifferentiated pluripotent stem cells that form teratomas 
in vivo, and this makes deriving pure cardiomyocyte populations vital for successful and safe 
cell therapy (Habib et al. 2008, Yoshida and Yamanaka 2011). 
Transplantation studies with hESC-derived cardiomyocytes (hESC-CM) have shown the 
ability of these cells to survive and mature after transplantation into mouse or rat hearts 
(Habib et al. 2008, Shiba et al. 2010, Dambrot et al. 2011). Cardiomyocytes derived by 
different methods have been shown to provide beneficial effect on contractile function both in 
infarcted and uninjured animal models (pigs, rats, mice) regardless of the differences in 
engraftment and survival enhancement methods (e.g. anti-oncotic/-apoptotic factors) (Binah 
et al. 2007, Habib et al. 2008, Shiba et al. 2010). Even though transplanted cells improved 
contractile function of the heart, they were often separated from the host myocardium by a 
fibrotic tissue, and the improvement was only seen in early time points (Habib et al. 2008, 
Mignone et al. 2010, Dambrot et al. 2011). Despite all the problems seen in transplantation 
studies they have provided a basis of novel regenerative cardiac therapy (Uosaki et al. 2011). 
Before human stem cell derived cardiomyocytes could be used in myocardial repair in 
therapeutical setting several problems have to be solved (Habib et al. 2008, Vidarsson et al. 
2010, Dambrot et al. 2011). These include efficient cardiomyocyte derivation, safe 
transplantation techniques and immune response prevention. 
In this literature review I will focus on presenting various cardiomyocyte differentiation and 
enrichment methods, as well as characterization techniques of human pluripotent stem cell 
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derived cardiomyocytes. In the experimental section we used embryoid body differentiation 
method to differentiate human pluripotent stem cells into cardiomyocytes. We used two 
human embryonic stem cell lines (HS346, HS181) and one induced pluripotent stem line 
(UEFhfiPS 1.4) which all produced functional cardiomyocytes with varying efficiency. 
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2 STEM CELLS 
   2.1 Classification of stem cells 
Stem cells are present in all organs and defined by their self renewal and capability to give 
rise to stem cells or more specialized cells (Filipczyk et al. 2007, Egashira et al. 2011). There 
are different types of stem cells with varying differentiation potentials. Stem cells of adult 
tissues with restricted differentiation potential are called multipotent as they can only give rise 
to cell types present in the surrounding tissues (Filipczyk et al. 2007, Rajala et al. 2011). Stem 
cells in the early developing embryo can give rise to all tissues of human body and are thus 
called pluripotent (Filipczyk et al. 2007). Only the first few cells of the human embryo are 
totipotent which means they are capable of deriving all tissues, including extra-embryonic 
tissues of amnion, chorion and other components of placenta needed for the formation of an 
embryo (Thorrez and Sampaolesi 2011). 
Pluripotent stem cells (PSC) have the ability to give rise to all three germ layers (endoderm, 
ectoderm, mesoderm) and thus differentiate to any cell type of human body (Vidarsson et al. 
2010, Thorrez and Sampaolesi 2011). They express pluripotency genes and cell-surface 
markers including OCT4, SOX2, Nanog, TRA 1-60, TRA-1-81, SSEA4 and alkaline 
phosphatase that can be used to identify PSC colonies (Dambrot et al. 2011, Thorrez and 
Sampaolesi 2011). These cells are immortal and can proliferate while maintaining the 
undifferentiated phenotype indefinitely under appropriate conditions. Because of the above 
characteristics, PSCs provide an inexhaustible source for cardiomyocytes which could be used 
in cardiac regenerative therapies that require large quantities of cells (Shiba et al. 2009). 
There are two pluripotent stem cell types, human embryonic stem cells and induced 
pluripotent stem cells, which have both been shown to fully differentiate into cardiomyocytes 
(Shiba et al. 2009, Kattman et al. 2011b). 
   2.2 Embryonic Stem Cells 
Human embryonic stem cells are isolated from the inner cell mass of donor blastocyst stage 
embryos left over from patients going through treatments for childlessness (Goh et al. 2005, 
Vidarsson et al. 2010, Dambrot et al. 2011). At blastocyst stage, which occurs on day 5 post-
fertilization, the embryo is comprised of an outer layer of cells (trophoectoderm) and inner 
cell mass (Habib et al. 2008, Dambrot et al. 2011). When deriving hESCs, the trophoectoderm 
is removed and cells from the inner cell mass are isolated. There are several culture systems 
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for maintaining and expanding hESCs in their undifferentiated state but typically they are 
grown on top of mitotically inactivated feeder cells (mouse or human fibroblasts) which help 
to retain the undifferentiated stage of ESCs and their ability to self-renew (Habib et al. 2008, 
Shiba et al. 2009,  Dambrot et al. 2011). However these direct co-cultures are not desirable 
when aiming for cell therapy applications, therefore, feeder-free systems have been developed 
(Shiba et al. 2009, Rajala et al. 2010, Vidarsson et al. 2010). It has been shown that hESCs 
can be maintained in their pluripotent state on Matrigel® (BD Biosciences)(extracellular 
matrix derived from mouse sarcoma), natural laminin or human extracellular matrices (e.g. 
laminin-511, vitronectin) with feeder-cell-conditioned or another defined media (Braam et al. 
2008, Rodin et al. 2010, Dambrot et al. 2011). Basic fibroblast growth factor (bFGF) is 
needed to keep the cells undifferentiated in vitro (Dambrot et al. 2011). When hESC are 
removed from the conditions needed for maintaining pluripotency and cultured in suspension, 
they form three-dimensional aggregates called embryoid bodies (EB). These structures 
contain endodermal, mesodermal and ectodermal cell types, resembling the early stages of 
embryonic development (Vidarsson et al. 2010, Dambrot et al. 2011, Rajala et al. 2011).  
There are some limitations in the use of hESC. Firstly there are the ethical concerns about the 
destruction of the embryo while deriving the cells (Filipczyk et al. 2007). Secondly, even 
though pluripotent cells provide desirable source for cardiac cells, at undifferentiated state 
they produce teratomas when injected to immunodeficient mice (Shiba et al. 2009, Mignone 
et al. 2010, Egashira et al. 2011). These benign tumors contain cell types from all three 
embryonic germ layers. Thirdly, characterization of a wide range of hESC lines has to be 
done because of the diverse genetic background of the donors, i.e. numerous individual 
embryos. Moreover, due to previous, the cell lines are likely to have different growth and 
differentiation characteristics (Goh et al. 2005, Habib et al. 2008). Every hESC line should 
also be studied for a longer period of time because of the chromosomal instability seen with 
extended culturing in vitro (Habib et al. 2008, Narsinh et al. 2011). Lastly, genetic differences 
between cell lines make immunological rejection also problem that must be taken into 
account and overcome before applying the cells in therapeutical setting (Goh et al. 2005, 
Thorrez and Sampaolesi 2011).  
   2.3 Induced Pluripotent Stem Cells 
Induced pluripotent stem cells are generated from somatic cells by introducing genes that are 
capable of reprogramming these cells into pluripotent, embryonic stem cell-like state (Barile 
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et al. 2011, Kattman et al. 2011b, Yoshida and Yamanaka 2011). First human iPSC lines were 
established from fibroblasts, a year after Takahashi and Yamanaka (2006) succeeded in 
reprogramming mouse somatic cells by introduction of four transcription factors; c-Myc, 
Oct3/4, SOX2 and Klf4 (Yamanaka factors) (Takahashi et al. 2007, Yu et al 2007, Choi et al. 
2011, Narsinh et al. 2011). These were followed by discovery of other four; Oct3/4, SOX2, 
Nanog and Lin28. Lin28 and Nanog were found to be able to substitute c-Myc and Klf4, well-
known oncogenes, and later it has been shown that several different combinations of these 6 
transcription factors are also able to induce pluripotency (Yu et al. 2007, Egashira et al. 2011, 
Narsinh et al. 2011). The transcription factors induce the expression of the host cells’ 
endogenous pluripotency genes (e.g. OCT4 and SOX2) and are supposed to be silenced as 
soon as these endogenous genes take over (Dambrot et al. 2011). Studies have shown that the 
number of the transcription factors can be lowered when the somatic cells that are used 
express endogenously stemness-related transcription factors (Choi et al. 2011, Narsinh et al. 
2011). Studies to replace the reprogramming factors with defined small molecules have also 
been made (Barile et al. 2010, Thorrez and Sampaolesi 2011). A change in the methylation 
pattern of DNA is one of the mechanisms involved with silencing of the genes. 
Reprogramming changes the DNA methylation pattern so that the somatic genes become 
silenced by methylation and pluripotency genes activated by demethylation (Thorrez and 
Sampaolesi 2011). 
IPSCs have numerous similar features with hESCs, including morphology, surface markers, 
gene expression, telomerase activity, teratoma formation in vivo and differentiation potential 
in vitro (Yu et al. 2007, Dambrot et al. 2011, Egashira et al. 2011, Kattman et al. 2011b, 
Narsinh et al. 2011). Human iPSCs have been successfully generated from fibroblasts (skin, 
oral mucosa, lung), keratinocytes, mesenchymal stromal cells, mobilized C34+ hematopoietic 
stem/progenitor cells and T-cells from peripheral blood (Barile et al. 2011, Dambrot et al. 
2011, Kattman et al. 2011b, Yoshida and Yamanaka 2011). Their advantage compared to 
hESCs is that hiPSCs does not require the destruction of embryos (Yamashita 2010, Kattman 
et al. 2011b, Narsinh et al. 2011, Thorrez and Sampaolesi 2011). Moreover, generation of 
hiPSCs make it possible to produce patient specific cells which could overcome the problem 
with immune response (Barile et al. 2011, Egashira et al. 2011, Kattman et al. 2011b). This 
technique has also enabled the generation of in vitro models for hereditable diseases, e.g. 
long-QT syndrome, as well as for sporadic diseases.  
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Initially transcription factors were transducted by retroviral or lentiviral vectors which 
integrate both the vector backbone and transgenes permanently into the genome (Takahashi et 
al. 2007, Kattman et al. 2011b, Thorrez and Sampaolesi 2011, Yoshida and Yamanaka 2011). 
Theoretically, these transgenes could interrupt the existing genes by altering their normal 
expression and causing tumor formation after transplantation, and also by disturbing the 
maintenance of undifferentiated state and further differentiation (Egashira et al. 2011, 
Narshinh et al. 2011, Thorrez and Sampaolesi 2011). Non-integrating methods that allow 
expression of pluripotency genes without integration the host genome have been developed to 
establish safer hiPSCs (Barile et al. 2011, Choi et. al 2011, Thorrez and Sampaolesi 2011). 
These include the use of non-integrating adenoviral vectors, plasmid vectors, sendai-viruses, 
recombinant proteins and synthetic messenger RNAs (Yoshida and Yamanaka 2011). Another 
gene delivery strategy is to use piggyBac transposons that integrate the cells but can be 
removed after iPS induction by transposase without leaving any genetic material behind (Choi 
et al. 2011, Thorrez and Sampaolesi 2011, Yoshida and Yamanaka 2011).  
Regardless of the various reprogramming methods, the derivation efficiency of hiPSCs can be 
as low as 0.001% to 0.01% of the starting cell population, which makes development of 
efficient strategies for hiPSC induction one of the main goals in iPSC research (Egashira et al. 
2011, Narsinh et al. 2011, Thorrez and Sampaolesi 2011). Several different growth factors, 
chemical compounds, transcription factors and microRNAs have been shown to improve the 
induction efficiency (Egashira et al. 2011, Dambrot et al. 2011, Yoshida and Yamanaka 
2011). Efficacy is not the only problem but there are also safety issues to be solved (Narsinh 
et al. 2011, Thorrez and Sampaolesi 2011). During reprogramming and culture, hiPSCs 
undergo dynamic changes in copy number and, as mentioned before, reactivation of 
transgenes in the cells might cause malignant cell growth after transplantation. Human iPSCs 
also retain epigenetic memory of the somatic cells they were derived, which means they favor 
differentiation along cell lineages related to the donor cell (Egashira et al. 2011, Kattman et 
al. 2011b, Thorrez and Sampaolesi 2011). This restricts their differentiation potential, but 
passaging of hiPSC cell lines has been shown to erase the epigenetic memory, making them 
more hESC like. As with hESCs, the long-term genetic stability of hiPSCs also needs to be 
demonstrated before these cells could be used in clinical setting (Habib et al. 2008, Choi et al. 
2011, Narsinh et al. 2011). 
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3 CARDIOMYOCYTE DIFFERENTIATION PROTOCOLS 
   3.1 Differentiation towards cardiac fate 
Formation of the mammalian heart happens in response to stereotyped patterns of timing, 
concentrations and combinations of different extracellular signaling proteins that guide the 
differentiation of pluripotent stem cells towards the cardiac fate (Mercola et al. 2011). 
Multiple studies have shown that the stem cell differentiation process can also be guided to 
the desired direction by adding or removing of these growth factors and hormones (Vidarsson 
et al. 2010, Egashira et al. 2011, Thorrez and Sampaolesi 2011). Although the molecular 
mechanisms in human cardiogenesis are not thoroughly known, the information gained from 
early cardiac development in animal models (chick, amphibians, zebrafish, mouse) has 
provided valuable information that can be applied when improving in vitro cardiomyocyte 
differentiation protocols (Vidarsson et al. 2010, Rajala et al. 2011, Thorrez and Sampaolesi 
2011). The understanding of the natural cardiomyogenesis is essential for recapitulating the 
regulatory mechanisms and their timing in early cardiac development, making it possible to 
generate highly enriched and differentiated cardiomyocyte populations (Habib et al. 2008, 
Egashira et al. 2011, Rajala et al. 2011, Thorrez and Sampaolesi 2011). 
Production of pluripotent stem cell derived cardiomyocytes has been demonstrated by several 
groups using varying differentiation methods which, despite the differences between hESCs 
and iPSCs, are applicable to both cell types (Goh et al. 2005, Thorrez and Sampaolesi 2011). 
Currently, the main approaches used are spontaneous embryoid body formation, co-culture 
with mouse endoderm-like cells, and guided differentiation method that uses defined growth 
factors supplemented either in EB-based cultures or in high-density monolayer models (Table 
1) (Dambrot et al. 2011, Rajala et al. 2011). The advantages and disadvantages of these 
methods will be discussed in this review. 
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Table 1. Different types of cardiomyocyte differentiation methods and their efficiencies. 
Method Differentiation efficiency (%) Ref. 
Spontaneous EB differentiation <1 Kehat et al. 2001 
Standard END-2 Co-culture  5 ─ 20 Mummery et al. 2003, 
Passier et al. 2005, Graichen 
et al. 2008, Xu et al. 2008b 
Modified END-2 Co-culture 20 ─ 25 Yoon et al. 2006, Graichen et 
al. 2008, Xu et al. 2008b, Liu 
et al. 2012 
Guided differentiation 30 ─ 50 Laflamme et al. 2007, Yang 
et al. 2008, Tran et al. 2009 
 
   3.2 Embryoid Body Formation 
Embryoid bodies (EBs) are three dimensional aggregates that consist of cells from all the 
three grem layers (ectoderm, endoderm and mesoderm) (Vidarsson et al. 2010, Rajala et al. 
2011). The spontaneous differentiation of EBs was the first method developed to obtain 
cardiomyocytes, still being the most common one (Kehat et al. 2001, Habib et al. 2008, Shiba 
et al. 2009). In this method, pluripotent stem cells are dispersed to small clumps of cells, 
removed from the conditions required to maintain pluripotency and placed in a suspension 
culture where they spontaneously form EBs (Kehat et al. 2001, Xu et al. 2002). The formation 
of EBs initiate and facilitate the differentiation process, as cell to cell interactions stimulate 
the gene expression for mesodermal and early cardiac cell lineages (Goh et al. 2005, 
Vidarsson et al. 2010, Rajala et al. 2011). Formed EBs are typically re-plated onto a matrix-
coated tissue culture plate, where after several days of culturing, contracting outgrowths 
appear (Kehat et al. 2001, Xu et al. 2002). This spontaneous differentiation can occur in 
regular growth medium supplemented with high concentration of fetal bovine serum, but the 
addition of growth factors and/or small molecules can further enhance and direct the 
differentiation towards the cardiac lineage (Shiba et al. 2009, Dambrot et al. 2011).  
Studies have shown that the heterogeneity among the aggregates, which differ in size and 
morphology, has adverse effects on the reproducibility and syncronicity of the differentiation, 
making it an important variable (Peerani et al. 2007, Bauwens et al. 2008, Rajala et al. 2011). 
To improve the differentiation efficiency and its reliability, different strategies have been 
developed to address this issue of size and shape (Vidarsson et al. 2010, Rajala et al. 2011, 
Thorrez and Sampaolesi 2011, Mummery et al. 2012). In hanging drop method cells are 
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aggregated in ‘hanging drops’ on a Petri dish lid where they form EBs (Yoon et al. 2006, 
Mummery et al. 2012). However, even though this method has been useful with mouse ESCs, 
it has not been very successful with hESC. In forced aggregation method defined number of 
dissociated hESC are centrifuged into a U- or V-shaped ultra-low attachment wells where 
they form identical sized EBs (Ng et al. 2005, Burridge et al. 2007). By varying the cell 
number, the size of the EBs can be controlled precisely. It has been suggested that the optimal 
size for human EB for cardiomyogenesis is between 250 to 300 µm on the third day of 
differentiation. Forced aggregation method has been considered quite practical, efficient and 
reproducible, especially when using defined growth factor conditions, making it a preferred 
method for high-efficiency differentiation that does not require a specialized apparatus. 
Increased efficiency of EB generation can also be achieved with a silicon wafer –based 
microfabrication technology (AggreWells, Stem Cell Technologies) as this high-throughput 
approach allows the production of hundreds of thousands EBs per square centimeter (Ungrin 
et al. 2008). Other ways to obtain uniform sized EBs are engineered microwells and 
micropatterning (Khademhosseini et al. 2006, Mohr et al. 2006). Microwells are fabricated 
wells of defined size that are coated with Matrigel for cell adhesion, where seeded hESCs 
grow in a conditioned medium or on feeder cells and fill the microwell, generating colonies of 
defined size. Removing the colonies from the wells results in defined sized cell aggregates, 
that can be used to further EB based differentiation. With this method, the optimal size for EB 
generation is 100 to 300 µm X-Y dimension, and 120 µm Z dimension (Mohr et al. 2010). 
Microwells have lesser background differentiation compared to 2-dimensional culture and the 
potential of scaling up, but this method is not yet commercially available (Mohr et al. 2006, 
Mummery et al. 2012). In micropatterning, hESC colonies of specified size are formed by 
plating cells in single cell suspension to micropatterned Matrigel islands. Varying the size of 
these islands (200µm/400µm/800µm) allow the control of the size of the colonies (Peerani et 
al. 2007, Bauwens et al. 2008). When these colonies are mechanically transferred into a 
suspension culture, defined sized EBs are generated. Micropatterning produces homogenously 
sized EBs and it has the potential for scaling up, but using this method requires microcontact 
printing equipment.  
Spontaneous EB formation is relatively simple and inexpensive method and therefore widely 
used, even though it is not the optimal way to obtain cardiomyocytes, especially for in vivo 
applications (Kehat et al. 2001, Rajala et al. 2011, Thorrez and Sampaolesi 2011). This is due 
to the various cell types present in EBs and the low and varying cardiomyocyte differentiation 
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efficiency, that can be as low as >1% (Table 1) (Kehat et al. 2001, Habib et al. 2008, Shiba et 
al. 2009, Rajala et al. 2011, Thorrez and Sampaolesi 2011). In addition, the efficiency is also 
highly dependent on the used cell line. However, protocols based on EB formation have been 
optimized by developing defined media, addition of growth factors and controlling the EB 
size, resulting in high-efficiency differentiation protocols (Mummery et al. 2012).  
   3.3 Co-culture with Stromal Cells 
Another widely used and more efficient approach to cardiomyocyte differentiation is based on 
co-culturing pluripotent stem cells with a visceral endoderm-like cell line (END-2) that has 
been derived from mouse P19 embryonal carcinoma cells (Mummery et al. 2003, Passier et 
al. 2005). Cardiomyocyte differentiation is induced either by co-culture with mitotically 
inactivated END-2 cells or by EB formation in suspension culture, using low attachment 
dishes and END-2 conditioned medium (Mummery et al. 2003, Passier et al. 2005, Graichen 
et al. 2008, Xu et al. 2008b). When using co-culture, PSCs are mechanically passaged as 
undifferentiated colonies onto mitotically inactivated END-2 cultures (Mummery et al. 2003, 
Passier et al. 2005, Freund et al. 2010). This method is based on the critical role of endoderm 
in the cardiac induction during the development of the heart (Filipczyk et al. 2007, Shiba et al. 
2009, Dambrot et al. 2011, Mummery et al. 2012). Initially, it was thought that 
cardioinductive signals of END-2 cells are due to cell to cell contact together with secreted 
factors simulating the presence of embryonic endoderm (Vidarsson et al. 2010, Rajala et al. 
2011, Xu 2012). However, as the END-2 conditioned medium (END2-CM), which is 
collected from the END-2 cell culture, is sufficient to induce the differentiation, cell-to-cell 
contact is not necessary.  
The use of serum-free medium has increased the efficiency of cardiomyocyte differentiation 
compared to the use of medium supplemented with fetal calf serum (Passier et al. 2005). The 
differentiation efficiency of EBs can be further enhanced by using END2-CM as a 
differentiation medium (Passier et al. 2005, Graichen et al. 2008, Shiba et al. 2010, Vidarsson 
et al. 2010, Thorrez and Sampaolesi 2011). Also adding of different small molecules has been 
shown to enhance differentiation and these will be discussed later. When using co-culture 
with stromal cells, the absence of insulin is also important, as it has been demonstrated to be a 
potent inhibitor of cardiogenesis, guiding the differentiation towards neuroectoderm instead 
(Freund et al. 2008, Xu et al. 2008b). 
22 
 
Co-culture with stromal cells has been demonstrated to be efficient in both hESC and hiPSCs 
(Mummery et al. 2003, Passier et al. 2005, Freund et al. 2010). It is useful when testing the 
ability of these cells to form mesoderm, as it requires a low number of cells, is simple and 
rapid, yielding a sufficient amount of cardiomyocytes for further characterization (Mummery 
et al. 2012). Appearance of contracting cardiomyocytes usually occurs within 12 days of co-
culture, the majority of produced cardiomyocytes (~85%) being ventricular type (Mummery 
et al. 2003, Passier et al. 2005, Freund et al. 2008, Graichen et al. 2008, Xu et al. 2008b). The 
efficiency of the standard END-2 co-culture (without any additional small molecules), is 
usually quite low, varying from 5 – 20 %, while modified protocols have been reported to 
result in preparations of 20 – 25 % of cardiomyocytes (Table 1). 
   3.4 Guided differentiation 
         3.4.1 Growth factors 
There are a number of growth factor families that have the ability to enhance mesoderm 
formation and cardiomyogenesis in PSCs, all of them being expressed in the early endoderm 
(Table 2) (Filipczyk et al. 2007, Habib et al. 2008, Dambrot et al. 2011, Vidarsson et al. 2010, 
Rajala et al. 2011). 
Table 2. Growth factor families and individual factors indentified to be essential for heart development. 
Growth factor family Growth factor Role 
TGF-β 
BMPs (BMP4, 
BMP2) 
 
  
Activin A 
 
Induction of cardiomyogenesis, promotion of 
mesoderm formation, specification of the 
myocardial lineage commitment 
 
Promotion of cardiogenesis 
 
Wnt 
Canonical Wnt/β-
catenin pathway, 
Wnt11 
Stage-dependent effects on cardiac differentiation 
FGF bFGF 
Influence in the survival and proliferation of 
cardiac precursors 
TGF-β – Transforming growth factor β, BMP – Bone morphogenic protein, Wnt – The wingless/INT, (b)FGF – 
(Basic) fibroblast growth factor 
 
Bone morphogenic proteins (BMPs) are members of the transforming growth factor β (TGF-
β) superfamily that play an important role in the induction of cardiomyogenesis as well as in 
promotion of mesoderm formation and specification of the myocardial lineage commitment 
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during differentiation (Filipczyk et al. 2007, Habib et al. 2008, Rajala et al. 2011). Another 
member of TGF-β superfamily, Activin A, has been demonstrated to promote cardiogenesis in 
PSCs (Habib et al. 2008, Shiba et al. 2009, Rajala et al. 2011). The fibroblast growth factor 
(FGF) family is also one of the regulators of cardiac development, considered to have 
influence in the survival and proliferation of cardiac precursors (Vidarsson et al. 2010, 
Mercola et al. 2011). Although not all members of this family have influence in heart 
development and/or their exact role is still unclear, it is evident that FGFs co-operate with 
BMPs to induce cardiomyogenesis (Filipczyk et al. 2007). The Wingless/INT (Wnt) protein 
family, especially the canonical Wnt/β-catenin pathway has stage-dependent effects on 
cardiac differentiation: activation of this pathway immediately in the beginning of the 
differentiation (e.g. with Wnt3a) leads to enhanced cardiomyogenesis by augmenting the 
formation of mesoderm, whereas after mesoderm formation, Wnt signaling has been shown to 
have inhibitory actions towards the pre-cardiac mesoderm (Habib et al. 2008, Shiba et al. 
2009, Paige et al. 2010, Mercola et al. 2011). It also affects the differentiation in later stages 
by promoting the formation of second heart field cardiac progenitor cells that give rise to right 
ventricle and outflow tract, but reduces their further differentiation into cardiomyocytes 
(Habib et al. 2008, Mercola et al. 2011). Also activators of non-canonical Wnt signaling 
(Wnt11) have been demonstrated to promote cardiac differentiation (Filipczyk et al. 2007, 
Habib et al. 2008, Mummery et al. 2012). 
There are many guided differentiation protocols using varying combinations of compounds to 
enhance the cardiac differentiation either in EB based culture or culture in high-density 
monolayer on matrigel coated plates (Table 3) (Vidarsson et al. 2010, Hudson et al. 2012, 
Mummery et al. 2012). Monolayer approach has been reported to be more efficient than the 
EB method, because the absence of complex diffusional barriers of EBs makes controlling the 
addition of growth factors and other interventions easier and more reproducible. In addition 
monolayer cultures do not require the replating steps that EB based cultures do, reducing the 
procedures and the use of supplies for tissue cultures (Laflamme et al. 2007, Yang et al. 2008, 
Tran et al. 2009). 
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Table 3. Examples of growth factors used in guided differentiation protocols and their efficiency 
Growth 
factors 
Additional 
factors used 
Culture type 
Cardiomyocyte 
yield (%) 
Ref. 
Activin A, 
BMP4 
- 
High-density monolayer PSCs  + 
serum-free medium 
>30 
Laflamme et al. 
2007 
Activin A, 
BMP4 
bFGF, DKK1, 
VEGF 
EB based  40-50 Yang et al. 2008 
Wnt3a or 
BMP4 
- 
EB based + subsequent 
reduction of serum and insulin 
50 Tran et al. 2009 
BMP4 – Bone morphogenic protein 4, bFGF – Basic fibroblast growth factor, DKK1 – Dickkopf homolog 1, 
VEGF – Vascular endothelial growth factor, Wnt3a – Wingless-type MMTV (mouse mammary tumor virus) 
integration site family, member 3A 
 
Improvements to these protocols are being made constantly, involving the use of different 
growth factors, small molecules and their combinations at various stages of the differentiation 
process (Dambrot et al. 2011, Mummery et al. 2012). Differentiation can be initiated with the 
use of just two growth factors, BMP4 and Activin A (Laflamme et al. 2007, Xu 2012). 
Generally, introducing Activin A, BMP4 and bFGF will start the differentiation of PSCs 
towards the cardiac lineage, and later addition of Wnt-inhibitor dickkopf homolog 1 (DKK1) 
and vascular endothelial growth factor (VEGF) will guide the further cardiac specification 
(Laflamme et al. 2007, Yang et al. 2008, Dambrot et al. 2011). It has also been demonstrated 
that the early introduction (days 0 to 2) of Wnt3a to hESC derived EBs increases mesoderm 
and cardiac differentitation, especially when Activin A is used at the same time (Tran et al. 
2009, Xu 2012). The timing when different compounds are introduced varies between 
different studies and research groups, although there are some similarities (Habib et al. 2008, 
Dambrot et al. 2011, Xu 2012).  BMP4 and Activin A are added first, usually on days 1 to 4, 
followed by VEGF and DKK1 (days 4 and after) (Laflamme et al. 2007, Yang et al. 2008, Xu 
2012). DKK1 is always added to the culture on later phases, because if it is administered too 
early, it will inhibit the formation of mesoderm thus decreasing the amount of produced 
cardiomyocytes (Yang et al. 2008, Paige et al. 2010, Kattman et al. 2011a, Mercola et al. 
2011). The timing of bFGF varies between studies, it can be added from the beginning (days 1 
to 4) or at the late stage of differentiation (days 8 and after) (Xu 2012). 
Combinations of growth factors, their concentration and timing are important variables in 
guided differentiation protocols and these might have to be adjusted for different cell lines, 
which is due to the variations in endogenous signaling between cell lines (Hudson et al. 2012, 
Mummery et al. 2012, Xu 2012). Depending on the guided differentiation protocol used, the 
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first contracting outgrowths were seen 10 – 23 days after induction of the differentiation, with 
efficiency varying from 30 – 50% (Table 3) (Laflamme et al. 2007, Takahashi et al. 2007, 
Yang et al. 2008, Shiba et al. 2009). Although guided differentiation protocols result in better 
efficiency in cardiomyocyte differentiation, the use of multiple growth factors make these 
methods costly (Ren et al. 2011, Mummery et al. 2012). 
         3.4.2 Small molecules 
Because many of the used growth factors are expensive, degrade rapidly and have variation in 
their bioactivity between different production batches, high-throughput molecular screening 
technology has been used to find novel small molecules that potentially induce 
cardiomyogenesis in vitro (Table 4) (Vidarsson et al. 2010, Rajala et al. 2011, Mummery et 
al. 2012). In addition, small molecules can penetrate multiple cell layers of EBs, when larger 
proteins may not be able to get into the core (Wang et al. 2011). 
Table 4. Small molecules that have been shown to have beneficial effect on CM-differentiation. 
Small molecule Mechanism of action Protocol 
5-aza-deoxycytidine Demethylating agent Spontaneous EB method 
Ascorbic acid Upregulates late-stage markers of cardiogenesis  All 
Cyclosporin-A Unknown END-2 
Prostaglandin I2  Unknown END-2 
p38MAPK inhibitors Inhibit p38MAPK All 
Cardiogenols Induces GATA4 and MEF2 All 
DMSO Chromatin remodeling All 
Sulfonyl hydrazones 
Induce Nkx2.5 and GATA4, increase cardiomyogenic 
miRNAs 
All 
Dorsomorphin Inhibits BMP signaling All 
SU5402 Inhibits FGF receptor All 
 Isoxazolylserines Regulate cardiomyocyte gene expression All 
 BIO (6-
bromoindirubin-3´-
oxime 
Activates canonical Wnt signaling All 
EB – Embryoid body, END-2 – Visceral endoderm-like cell line, p38MAPK – P38 mitogen activated protein 
kinase, GATA4 – Zinc finger transcription factor, Nkx2.5 – Nk2 transcription factor related locus 5, miRNA – 
micro RNA, BMP – Bone morphogenic protein, FGF – Fibroblast growth factor, Wnt – Wingless/Int –protein 
family 
The spontaneous cardiomyocyte differentiation method from EBs can be enhanced further by 
incubating the cells in hypoxic conditions and using the demethylating agent 5-aza-
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deoxycytidine (Yoon et al. 2006). Ascorbic acid promotes cardiac differentiation by 
increasing collagen synthesis and by enhancing the proliferation of cardiac progenitor cells 
via MEK-ERK1/2 pathway, upregulating the late-stage markers of cardiogenesis (Takahashi 
et al. 2003, Cao et al. 2012). Cyclosporin-A increases the induction of cardiac progenitors and 
cardiomyocytes from mesoderm by 10 – 20 times, although the mechanism of action is still 
unknown (Yoon et al. 2006, Xu et al. 2008b, Fujiwara et al. 2011). These both have been 
beneficial for the differentiation with END-2 cell based protocols. Furthermore, the addition 
of prostaglandin I2 (PGI2), which is secreted by END-2 cells, into a fully synthetic serum-
free medium resulted in similar cardiogenic activity as in END-2 conditioned medium (Xu et 
al. 2008b). P38 mitogen activated protein kinase (p38MAPK) has been found to negatively 
regulate the generation of cardiomyocytes from hESC (Graichen et al. 2008, Xu et al. 2008b, 
Liu et al. 2012). Studies have shown that p38MAPK inhibitors (e.g. SB203580, PD169316) 
induce cardiomyogenesis and have beneficial effect on cardiomyocyte differentiation in both 
END-2 conditioned medium systems and in serum- and insulin-free medium systems with 
high concentrations of PGI2. The positive effect of these inhibitors is highly depended on the 
used dose, as low concentrations induce and high concentrations reduce the efficiency of 
cardiomyocyte differentiation. 
Other small molecules have been identified as enhancing factors in cardiac differentiation 
based on their ability to upregulate late-stage markers of cardiogenesis (Rajala et al. 2011, 
Thorrez and Sampaolesi 2011, Liu et al. 2012). These include cardiogenols that induce 
GATA4 and MEF2, which are transcription factors involved in cardiac development. Sulfonyl 
hydrazones and isoxazolylserines have also been identified as cardiomyocyte differentiation 
stimulating factors (Wei et al. 2004, Rajala et al. 2011, Liu et al 2012). However, it is not 
quite clear whether sulfonyl hydrazones and isoxazolylserines have direct effect on the 
cardiogenesis or if they stimulate other cell populations activating cardiac development. BMP 
singnaling inhibitor dorsomorphin and FGF receptor inhibitor SU5402 have a positive effect 
on cardiomyocyte differentiation (Dambrot et al. 2011, Xu 2012). Glycogen synthase kinase 3 
(GSK3) inhibitor BIO (6-bromoindirubin-3´-oxime), that activates canonical Wnt signaling, 
has been found to improve cardiac differentiation when followed with inhibition of Wnt 
signaling  (Dambrot et al. 2011, Mummery et al. 2012). 
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4 PURIFICATION OF HESC/IPSC DERIVED CARDIOMYOCYTES 
   4.1 Purification methods 
Despite all the improvements made to differentiation protocols, none of the various methods 
result in homogenous, well characterized populations of cardiomyocytes, which makes 
developing stable and effective purification methods essential (Vidarsson et al. 2010, Thorrez 
and Sampaolesi 2011). The goal is to isolate cardiomyocytes from the heterogeneous pool of 
cell types, including remaining undifferentiated pluripotent stem cells, to gain highly enriched 
cardiomyocyte populations (Habib et al. 2008, Thorrez and Sampaolesi 2011). These 
purification methods are based on genetic modification of hPSCs or the characteristics of 
cardiomyocytes or cardiac progenitors (Xu 2012). Different purification methods are 
introduced in table 5. 
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Table 5. Cardiomyocyte purification methods 
Purification method Advantages Disadvantages 
Enrichment 
efficiency (%) 
Ref. 
Micro dissection Inexpensive Labor-intensive 50-80 
Kehat et al. 2001 
Caspi et al. 2007 
    
Low purity cell 
populations  
    Lack of scalability   
 
Percoll® Gradient 
centrifugation 
Inexpensive Labor-intensive 70-95 
Xu et al. 2002 
Xu et al. 2006 
Laflamme et al. 
2007 
 
  
Low purity cell 
populations  
 
  
Suitable for late stage 
CMs (after day 15); less 
efficient for early stage 
CMs 
  
 
  Lack of scalability 
  
Genetic selection 
Highly enriched cell 
populations 
Expensive >90 
Kolossov et al. 
2005 
Anderson et al. 
2007 
    
Requires genetic 
modifications 
  
Huber et al. 2007 
Xu et al. 2008 
    Cell line dependent   
 
    Possible tumorigenesis   
 
Cardiac mesoderm or 
progenitor surface markers 
(KDRlow/C-KITneg, 
KDR+/PDGFR-α+, SSEA-1+) 
Enhanced 
cardiomyocyte 
yield 
Isolation time has 
narrow window 
Depends on the cell 
surface protein used; 
varies from 50-80 % 
after further culture 
Yang et al. 2008 
Blin et al. 2010 
Kattman et al. 
2011a 
 
Cardiomyocyte surface 
proteins (VCAM+, ALCAM+, 
SIRPA+) 
VCAM+, SIRPA+: 
Suitable for both 
early and late stage 
cardiomyocytes 
Antibodies are bound to 
final cell preparation 
VCAM: 95%, MACS-
purified, SIRPA+: 98% 
FACS-purified, 
ALCAM+: 60%, MACS-
purified 
Rust et al. 2009 
Dubois et al. 2011 
Elliot et al. 2011 
Uosaki et al. 2011 
    
ALCAM+ only suitable for 
early-stage CMs 
  
 
Mitochondrial labeling with 
TMRM 
Highly enriched cell 
populations 
Suitable for late stage 
CMs (day 20 or after); 
less efficient for early 
stage CMs 
>99 Hattori et al. 2010 
 
Simple 
   
 
Scalable 
   
 
Does not affect cell 
viability    
FACS – Fluorescence-activated cell sorting; MACS – Magnetic-assisted cell separation; KDR – Kinase insert 
domain receptor; C-KIT – Proto-oncogene, type 3 transmembrane receptor for MGF (mast cell growth factor, 
also known as stem cell factor); SSEA-1 – Stage-specific embryonic antigen 1; VCAM1 – Vascular cell 
adhesion molecule 1; SIRPA – signal-regulatory protein alpha; ALCAM – Activated leukocyte cell adhesion 
molecule; TMRM – Tetramethylrhodamine methyl ester perchlorate 
 
   4.2 Micro dissection and Percoll® gradient centrifugation 
 
The most widely used enrichment approaches are the labor-intensive micro dissection and 
Percoll® gradient centrifugation (Vidarsson et al. 2010, Thorrez and Sampaolesi 2011). 
Micro dissection is based on mechanical isolation of the contracting areas by manually 
dissecting them from the non-beating cell material (Kehat et al. 2001, Caspi et al. 2007, 
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Thorrez and Sampaolesi 2011). In Percoll® density gradient separation approach 
enzymatically dissociated cells are loaded into Percoll’s two layers and centrifuged, making 
the majority of cardiomyocytes reside on the lower level (Xu et al. 2002, Xu et al. 2006, 
Laflamme et al. 2007). This is based on the unique bouyant properties of cardiomyocytes, 
isolating them on the basis of their comparably larger size and higher density, resulting in 
three- to seven-fold enrichment (Xu et al. 2002, Xu et al 2006, Laflamme et al. 2007, Rajala 
et al. 2011). This technique has limitations, as it is efficient only for late-stage hESC derived 
cardiomyocytes (>15 days) and when the differentiated culture contains high percentage of 
cardiomyocytes (Xu et al. 2002, Xu et al. 2006). The biggest disadvantages of both of the 
above approaches are the lack of scalability, insufficient purity and labor-intensiveness (Xu et 
al. 2002, Xu et al. 2006, Laflamme et al. 2007, Mummery et al. 2012). 
   4.3 Genetic selection 
Highest level of cardiac purity has been obtained using genetic selection, where 
undifferentiated hESCs are modified to carry a fluorescent reporter (usually enhanced green 
fluorescence protein, eGFP) or mammalian selection gene (e.g. antibiotic resistance) under 
the transcriptional control of a cardiomyocyte associated promoters such as contractile 
element proteins MYH6 (α-myosin heavy chain; α-MHC) or MYL2 (ventricular myosin light 
chain; MLC2V) (Kolossov et al. 2005, Huber et al. 2007, Xu et al. 2008a, Kattman et al. 
2011b, Xu 2012). After modification these cells are differentiated into cardiomyocytes and 
the transgenic cells are selected based on activation of the cardiac promoters. This can be 
done by using fluorescence activated cell sorting (FACS) or antibiotics depending on if the 
transgene encodes a fluorescence protein or polypeptides rendering antibiotic resistance. The 
genetic selection method results in cardiomyocyte population as high as >90%. The biggest 
problem regarding this approach is the risk of genetic modification that can lead to 
tumorigenesis (Xu et al. 2008a, Shiba et al. 2009, Egashira et al. 2011). In addition, this 
method has not been successful in all hESC lines and thus might not be usable routinely in 
hiPSCs either (Dambrot et al. 2011, Xu 2012). 
Double transgenic modification of hESCs has also been used to gain significantly enriched 
populations of cardiomyocytes (Anderson et al. 2007, Habib et al. 2008, Rajala et al. 2011). 
This has been achieved by either using a vector expressing eGFP gene for visualization and 
drug resistance gene for positive selection, or by using a negative selection based on the 
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herpex simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system to 
eliminate proliferating non-cardiac cells. 
   4.4 Cell-surface proteins 
          4.4.1 Cardiac progenitor surface markers 
Enriched cardiomyocyte populations can also be gained by selecting cardiomyocyte 
progenitors or differentiated cardiomyocytes, by using antibodies based on the expression of 
cell-surface proteins (Yamashita 2010, Dambrot et al. 2011, Xu 2012). This has proven to be 
quite challenging due to the lack of cardiomyocyte-specific cell-surface markers and the 
transient expression of cardiac progenitor surface markers (Vidarsson et al. 2010, Rajala et al. 
2011, Xu 2012).  
Regardless of the lack of specific surface markers for differentiated cardiomyocytes, the 
selection of cardiac progenitors by their unique surface marker expression has resulted in high 
purity cardiomyocyte populations after further differentiation (Xu 2012). Cardiac mesodermal 
cells have been enriched from heterogenous cell population based on their relatively low 
expression of kinase insert domain-containing receptor (KDR; also known as fetal liver kinase 
1; Flk1) and absence of stem cell marker c-Kit expression (Yang et al. 2008). Differentiation 
towards mesodermal faith was inducted in serum free media with the combination of activin 
A, BMP4, bFGF, VEGF and DKK1. The selected cells expressed high levels of cardiac 
transcription factors, and after further culturing generated populations of over 50% of 
cardiomyocytes. Platelet-derived growth factor receptor-α (PDGFR-α) has been found to be 
co-expressed in mesoderm with KDR, and by selecting progenitor cells for further 
differentiation based on their co-expression, over 80% of the cells differentiated to 
cardiomyocytes (Kattman et al. 2011a). Even though KDR has proven to be useful marker for 
selecting cardiac progenitors from heterogeneous cell populations, it has a major disadvantage 
of being also expressed in undifferentiated hESCs as well as in progenitor cells for endothelial 
and smooth muscle cells (Yang et al. 2008, Yoshida 2010, Dambrot et al. 2011, Mummery et 
al. 2012). 
 
Cardiac progenitor cells have also been isolated based on their expression of stage-specific 
embryonic antigen-1 (SSEA-1) (Blin et al 2010). This was done with hPSCs cultured on 
mouse feeders and treated with BMP2 and FGF inhibitor SU4502. Generated SSEA-1
+
 cells 
expressed a variety of cardiac progenitor markers and were able to differentiate into 
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cardiomyocytes, endothelial cells and smooth muscle cells. However, all hPSCs in their early 
stage of differentiation express this marker, making it an inappropriate selection method for 
cardiac lineage only. 
It is still unknown whether the progenitor cells isolated based on the expression of these 
different markers are completely different cell populations, or similar cells at varying 
differentiation stages (Xu 2012). Although differentiated cultures from these progenitors 
contain high percentages of cardiomyocytes, high purity cannot be guaranteed as the 
progenitors that give rise to cardiomyocytes also have the ability to differentiate into 
endothelial and smooth muscle cells. 
         4.4.2 Cardiomyocyte surface markers 
Cardiomyocyte specific surface markers have been identified recently, making it possible to 
enrich cardiomyocytes by positive selection based on the expression of these markers, or by 
negative selection with non-cardiac markers (Mummery et al. 2012, Xu 2012). This can be 
done with either FACS or magnetic-assisted cell separation (MACS) (Xu 2012). Two surface 
markers have been found to associate with hPSC derived cardiomyocytes; vascular cell 
adhesion molecule 1 (VCAM1) and signal regulatory protein α (SIRPA) (Dubois et al. 2011, 
Elliot et al. 2011, Uosaki et al. 2011). Using FACS to select SIRPA
+
 cells has resulted in 
highly enriched cardiomyocyte populations where 90 - 98% were positive for cardiac troponin 
T (cTnT) which is one of the structural proteins in myofilaments of cardiomyocytes (Dubois 
et al. 2011). VCAM1
+
 cell populations selected by MACS contained about 95% of cTnT 
positive cells (Uosaki et al. 2011). In addition, activated leukocyte cell adhesion molecule 
(ALCAM) has been used to select cardiomyocytes from heterogenous population of 
differentiated cells (Vidarsson et al. 2010, Rajala et al. 2011, Uosaki et al. 2011, Xu 2012). 
MACS selection for ALCAM has been shown to result in an enriched population in which 
58% of CMs are positive for both ALCAM and MHC-α. 
Although above methods have resulted in highly enriched cardiomyocyte populations, there 
are some things that need to be considered. Studies have shown that using SIRPA or VCAM1 
in enrichment will result in losing of some of the cardiomyocytes as all of them do not 
express these markers (Dubois et al. 2011, Uosaki et al. 2011). It is also not known if 
ALCAM is co-localized with either of these markers, or if it identifies a totally different 
cardiomyocyte population (Xu 2012). 
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Alternative enrichment method is negative selection in which non-cardiac cells are first 
targeted by surface markers and thereafter removed from the cell populations (Dubois et al. 
2011). Examples of these are THY1 (fibroblasts), PDGFRB (smooth muscle cells), PECAM1 
(endothelial cells) and ITGA1 (laminin/collagen receptor) that have been identified from non-
cardiac cells in differentiated populations.  
 
   4.5 TMRM 
Tetramethylrhodamine methyl ester perchlorate (TMRM), a fluorescent dye that labels active 
mitochondria, has been proven to be a promising compound for isolating cardiomyocytes 
from mixed cell populations (Hattori et al. 2010). This method is based on the high 
mitochondrial content of cardiomyocytes and does not require genetic modifications of the 
cells. It is a simple purification method, it does not affect cell viability and fluorescence 
disappears completely after 24 hours, indicating the rapid removal of the dye from the cells. 
Cells can be sorted selectively by FACS from the fraction with high fluorescence intensity, 
while non-cardiac and dead cells are in lower fluorescence fractions (Hattori et al. 2012, Xu et 
al. 2012).  This has resulted in cardiomyocyte populations higher than 99%. However, this 
dye is applicable only in the late-stage of differentiation (day 20 or after). In addition, with 
this method some of the cardiomyocytes are lost since the number of cardiomyocytes 
collected by TMRM staining was only 60-90% of the number of cardiomyocytes collected 
based on their α-actinin expression. 
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5 CHARACTERIZATION 
   5.1 Cardiac marker expression 
Characterization of hPSC derived cardiomyocytes is essential for determining the success of 
differentiation protocols, and it is based on the expression of specific molecular markers, 
structural architecture and functionality compared to cardiomyocytes from adult human 
myocardium (Vidarsson et al. 2010, Rajala et al. 2011, Mummery et al. 2012). The first sign 
of the success is the appearance of contracting areas, but more accurate methods have to be 
used to confirm the actual cardiac phenotype (Mummery et al. 2012, Xu 2012). 
In the developing embryo, after the gastrulation, development of cardiomyocytes can be 
summarized in four steps: first the generation of mesoderm is initiated, leading to formation 
of cardiogenic mesoderm and cardiac mesoderm, finally resulting in maturation of early 
cardiomyocytes (Habib et al. 2008, Rajala et al. 2011, Thorrez and Sampaolesi 2011). Every 
step has its own distinct markers; hence differentiation of PSCs into cardiac cells can be 
characterized e.g. by the transcription factor expression of the different development stages. 
After the differentiation is initiated, stem cell markers are downregulated and cardiac 
mesoderm markers upregulated, followed by the upregulation of cardiomyocyte specific 
genes (Xu 2012). 
Cardiomyocytes derived from hPSCs express several markers similar to mature 
cardiomyocytes including structural proteins, transcription factors, ion-channels, hormones 
and tight junction proteins (Table 6) (Habib et al. 2008, Rajala et al. 2011, Liu et al. 2012). 
NK2 transcription factor related locus 5 (Nkx2.5), T box protein 5 (Tbx5) and LIM 
homeodomain transcription factor 1 (Isl-1) are activated shortly after the heart fields are 
formed in the fetus, being among the earliest markers of the cardiac lineage (Filipczyk et al. 
2007, Mummery et al. 2012). Nkx2.5 and Tbx5 associate with zinc finger transcription factor 
(GATA) family and serum response factor (SRF), activating cardiac structural genes (MLC, 
MHC, actin, troponins and desmin), which are also regulated by myocyte enhancer factor 2C 
(MEF2C). GATA4 is essential in the formation of heart tube and later in the formation of 
proepicardium and muscle development. The expressions of atrial natriuretic factor (ANF), a 
hormone expressed in atrial and ventricular cardiomyocytes, and gap junction protein 
connexin 40 are also activated by co-operation of Nkx2.5 and Tbx5. Gap junction proteins, 
like N-cadherin and connexin 40 are necessary for the electro-mechanical coupling between 
cells (Xu 2012). The interactions between these transcription factors control the 
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differentiation, maturation and proliferation of cardiomyocytes, making many of them useful 
when identifying the differentiation stage and the degree of maturity of generated 
cardiomyocytes, due to the tight temporal expression of these factors during the 
differentiation (Filipczyk et al. 2007, Mummery et al. 2012). Reverse transcription-
polymerase chain reaction (RT-PCR) can be used to evaluate the expression of cardiac 
specific genes and transcriptional factors (Habib et al. 2008, Mummery et al. 2012). 
Table 6. Cardiac markers used for characterization of hPSCs derived cardiomyocytes 
Transcription factors GATA-4 
  Nkx2.5 
  Isl-1 
  Tbx-5 
  Tbx-20 
  MEF2C 
Structural proteins α-actinin 
 
cTnT 
 
cTnI 
 
α/β/sarcomeric-MHC 
 
MLC2a 
 
MLC2v 
 
Desmin 
 
Tropomyosin 
Gap junction proteins N-cadherin 
  Connexin 43 
Surface proteins and ion channels α1-adrenergic receptor 
 
β1-adrenergic receptpr 
 
L-type calcium channel 
Other cardiac spesific proteins ANF 
  CK-MB 
  Myoglobin 
Gata4 – Zinc finger transcription factor 4, Nkx2.5 – NK2 transcription factor related locus 5, Isl-1 –LIM 
homeodomain transcription factor 1, Tbx5/Tbx20 – T box protein 5/20, MEF2C – Myocyte enhancer factor, 
cTnT – cardiac troponin T, cTnI – cardiac troponin I, MHC – Myosin heavy chain, MLC2a – Myosin light chain 
(atrial), MLC2v – Myosin light chain (ventricular), ANF – Atrial natriuretic factor, CK-MB – creatine kinase-
MB 
 
The expression of structural components of myofibres can be demonstrated with 
immunocytochemistry, which is useful for evaluating the expression of cardiac markers but 
also for obtaining information of their subcellular localization (Goh et al. 2005, Filipczyk et 
al. 2007, Xu 2012). Immunolabeling with antibodies can be done to a variety of myofilament 
proteins such as α-MHC, β-MHC, MLC2a, MLC2v, cTnT, cTnI and α-actinin, which can 
then be observed with immunofluorescence microscopy (Goh et al. 2005, Mummery et al. 
2012). This is done to demonstrate the organized myofilament structure of the early 
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cardiomyocytes. Two members of the troponin complex (cTnT, cTnI) detected in the hPSC-
CMs play role in providing of calcium sensitive molecular switch that is needed in regulating 
the striated muscle contraction (Goh et al. 2005, Rajala et al. 2011, Liu et al. 2012). The 
expression of cardiac and muscle-specific creatine kinase-MB (M, muscle; B, brain) and 
myoglobin suggest that high energy transfer mechanism is present in these cells. The presence 
of α- and β-adrenergic receptors can be demonstrated by using different pharmacological 
agents, for example studies with phenylephrine and isoprenalin which act through these 
receptors have shown induction of concentration-dependent increase in beating rates.  
   5.2 Functional properties 
Studies have shown that hPSC derived cardiomyocytes display the functional properties of 
early-stage human heart cells with varying morphologies including atrial-, ventricular-, and 
pacemaker/conduction system-like morphologies (Habib et al. 2008, Vidarsson et al. 2010, 
Rajala et al. 2011, Mummery et al. 2012). Functional assays are used for further 
demonstration of the cardiac phenotype and functional properties, as cardiomyocytes should 
be able to generate action potentials (AP) that propagate the electric signal in the 
myocardium, resulting in intracellular Ca
2+ 
release and contraction of the cell.  
Although studies have shown that hPSC derived cardiomyocytes are able to generate APs, 
they exhibit immature AP parameters, such as slower AP upstroke, automaticity and relatively 
depolarized maximum diastolic potential, compared to their mature counterparts (Rajala et al. 
2011). Microelectrode recordings can be used to detect APs, and their properties can also be 
studied (e.g. the amplitude of the AP, spontaneous phase 4 depolarization, duration and rate of 
rise) (Mummery et al. 2012). Patchclamp method can be used to study the ionic currents 
causing APs in single cells, helping to determine the phenotype and the degree of maturation 
(Ren et al. 2011, Mummery et al. 2012, Xu 2012). Possible typical intracellular Ca
2+
 
transients can be detected by fluorescent labeling of Ca
2+
. PSC derived cardiomyocytes have 
been reported to exhibit at least a fast sodium current, L-type calcium current, pacemaker 
currents, and transient inward and outward rectifier potassium currents (Rajala et al. 2011). 
Even though the rise in intracellular calcium triggers the action potentials in hPSC derived 
cardiomyocytes, the regulation of calcium handling has been shown to differ from the mature 
cardiomyocytes. This is probably due to the immature sarcoplasmic reticulum in these cells. 
The function of L-type calcium channels has also been studied by inhibiting them with 
diltiazem and verpamil. 
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In addition to these methods, microelectrode array mapping technique is used to demonstrate 
the functional syncytium with pacemaker activity and propagation of action potentials with 
single-cell resolution (Mummery et al. 2012, Xu 2012). Multielectrode array mapping 
techniques do not provide information on single cell level, but it can be used to detect 
spontaneous electric signals (field potentials) and monitor electrophysiological properties of 
multicellular preparations (e.g. conduction velocity). They are also technically less 
demanding and more rapid than microelectrode arrays. Combining these molecular and 
functional assays is essential when confirming the cardiac identity of the cells. 
In general, hPSC derived cardiomyocytes express fairly immature phenotype and have an 
immature sarcoplasmic reticulum function (Rajala et al. 2011). They also display negative 
force-frequency relation, responding in opposite manner to increased stimulation as mature 
cardiomyocytes. Because of these differences, it is important to find out strategies to generate 
more mature cardiomyocytes, as studies have shown that hPSC derived cardiomyocytes 
mature over time in culture but do not reach full maturity (Goh et al. 2005, Rajala et al. 2011).  
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6 AIMS OF THE STUDY 
The main aim was to differentiate functional cardiomyocytes from several human embryonic 
and induced pluripotent stem cell lines by a method based on embryoid body formation.   
The more specific aims were: 
I To study cell line dependency on the efficiency to produce cardiomyocytes. 
II     To study the effect of the embryoid body size on the differentiation. 
III   To search for the optimal enzymatic treatment to achieve single cell suspension 
from beating clusters for further analyses. 
IV   To study if TMRM would be a suitable method for purification of 
cardiomyocytes from heterogenous cell populations produced during embryoid 
body formation. 
V    To confirm at RNA and protein level that the produced cells were functional 
cardiomyocytes. 
We used two human embryonic stem cell lines (HS346; HS181) and one induced pluripotent 
stem cell (iPSC) line (UEFhfiPS 1.4). The latter had been induced from human skin 
fibroblasts by introducing four genes (Oct-4, Klf-4, c-Myc and Sox-2) via lentiviral vector.  
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7 MATERIALS AND METHODS 
   7.1 Stem Cell culture 
Undifferentiated human pluripotent stem cells were thawn and cultured on feeder cells 
(human foreskin fibroblasts; CRL-2429, ATCC) that have gone through mitotical inactivation 
by mitomycin (10 µM; 2.5 h incubation (incubator 37°, 5% CO2)). ESC-lines (HS181, 
HS346) had been derived in the lab of Prof. Outi Hovatta in Karolinska Institutet, Stockholm, 
Sweden and iPSC-line (UEFhfiPS 1.4) in our lab. Embryonic stem cell medium (ES-medium) 
was Knockout™ DMEM (cat. 10829-018) supplemented with  20% Knockout™ Serum 
Replacement (cat. 10828-028), 2 mM Glutamax™ -I (cat. 35050-038), 50 IU/50µg/ml 
Penicillin-Streptomycin (cat. 15140-122), 0.1 mM 2-mercaptoethanol (cat. 31350-010; all 
above purchased from Invitrogen, Paisley, UK) and 1% Non-essential amino acids (Sigma 
Aldrich, Ayrshire, UK; cat. M7145) with 8 ng/ml basic fibroblast growth factor (b-FGF, R&D 
Systems, Minneapolis, MN, USA; cat. 234-FSE, carrier-free) (10 ng/ml for iPSCs). ES-
medium was changed every day and cells were passaged every 5-7 days. Prior to starting the 
differentiation, stem cell colonies were passaged onto matrigel coated dishes in mTeSR1-
medium (StemCell Technologies, Vancouver, Canada; cat. 05850). This step was done to 
achieve feeder-free cell cultures. mTeSR-1-medium was changed every second day. 
   7.2 Cardiac differentiation 
After the stem cell colonies were cultured for 5 to 7 days on matrigel, differentiated areas 
were cut off by scalpel and removed. Dish was washed once with DMEM/F-12 (Invitrogen; 
cat. 21331-020). Dispase solution (StemCell Technologies, Vancouver, Canada; cat. 07923) 
was added on the dish and incubated for 4 - 7 minutes in the incubator, to help the detachment 
of the remaining colonies. Dispase was removed and the dish gently washed with DMEM/F-
12. Cells were detached from the dish as clusters by pipetting DMEM/F-12 up and down upon 
the colonies and moved into 15 ml centrifugation tube. To carefully collect all of the cell 
material, the dish was washed with DMEM/F-12 and this was added into the same tube. After 
centrifugation (200G, 5 min, 25°C), supernatant was removed and ES-medium without FGF 
was added into the tube. Cell pellet was gently re-suspended and Rho kinase (ROCK)-
inhibitor Y-27362 (Sigma, St Louis, MO, USA; cat. Y0503) (10µM) was added to prevent 
cell death (Watanabe et al. 2007). Cell suspension was divided into two wells of ultra low 
attachment 6-well plate (Costar®, Corning, NY, USA; cat. 3471). Cells were cultured for 5 
days to form embryoid bodies (EB) and ES-medium was changed every second day. 
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4 well plates (Nunclon™ ∆Surface; cat. 176740) or 96-well plates (Nunc U96 MicroWell™ 
Plates; cat. 268200) (see figure 1) were coated with gelatin (Embryomax® Ultrapure water 
with 0.1% Gelatin, Millipore; cat. ES-006-B) for 30 min at room temperature (RT). Pre-
warmed cardiomyocyte medium (CM-medium) that contained KO DMEM, 20% Hyclone 
FBS (Fetal Bovine Serum; Defined 40nm filtered, South Logan, UT, USA; cat SH3007003), 
2 mM Glutamax™ -I, 1% Non-essential amino acid and 50 IU/50µg/ml Penicillin-
Streptomycin, 0.1 mM 2-mercaptoethanol was added to plates and 6 - 8 embryoid bodies were 
pipetted into each well in 4-well plates. In 96-well plate, one EB was pipetted to each well. 
CM-medium was changed every second day. The wells were monitored for beating clusters 
from day 6 onward. Cells were cultured on the plates until sufficient amount of beating 
clusters was achieved or when the occurrence of new beating clusters ceased. All the culturing 
times and studies made for different cell lines and differentiation batches are shown in figure 
1. 
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Figure 1. Studies made for each differentiation batch and cell line, and their timing. Timelines are put in 
order by the cell line. ULA-plate, Cells moved to Ultra Low Attachment dishes; Gelatin, EBs plated on gelatin 
(4-well plates if not said otherwise); Microdissection, microdissection of the beating areas; Re-plating (on glass 
bottom dishes), done only if dissociation of the beating clusters successful; MHC, myosin heavy chain –staining; 
Actin, actin staining; TMRM, staining with mitochondrial dye TMRM. 
 
   7.3 Cardiomyocyte purification 
         7.3.1 Preparation of single cell suspension 
Beating areas containing the differentiated cardiomyocytes were microdissected with injection 
needles (Terumo Neolus 27G 0.4X20mm; cat. NN-2719R) as carefully as possible, avoiding 
41 
 
cutting the surrounding cell material, and moved into one eppendorf tube with CM-medium. 
Two replicate samples of non-beating cell material were cut from the same wells as the 
beating areas and used as a control in all studies. As most of the further analyses would 
require single cell suspension, we tested different compounds to dissociate beating clusters to 
single cells (Figure 1). 
Test 1 Test 2 Test 3 
 
 
Figure 2. Different compounds and techniques tested for dissociating the beating clusters. 
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In test 1, Accutase™ (Stem Cell Technologies, San Diego, CA, USA; cat. 07920) was added 
and the samples were incubated in Thermomixer (Eppendorf Thermomixer Comfort, 
Eppendorf AG, Germany) for 30 min. To break the cell clusters, cells were pipetted up and 
down every 10 min, after which CM-medium was added to deactivate the enzyme and 
centrifuged (500G, 5 min). Supernatant was removed and the cell pellet was resuspended in 
CM-medium. 
As the first test did not produce single cell suspension, in the test 2 TrypLE™ Express 
(Invitrogen, Naerum, Denmark; cat. 12604-13) was added to the cell clumps. Since the initial 
8-min incubation time did not separate the cells from each other, we extended the incubation 
time to 20 min and tried to enhance it by pipetting the cells up and down in every 5 min. Still 
this method failed to separate the cells from each other.  
The third compound we tested was collagenase (8 U/ml; Collagenase Type II 190 U/mg 
(Worthington, Lakewood, CO, USA; cat. LS004177) – pancreatin (5 mg/ml; Pancreatin 
(Sigma Aldrich, Saint Louis, MO, USA; cat. P3292) solution in distilled H2O with 10% 
Penicillin-Streptomycin). The solution was diluted 1:10 with sterile PBS (Dulbecco’s 
Phosphate Buffered Saline, Sigma Aldrich; cat. D8537) before adding 1 ml into the tubes 
which were then incubated in Thermomixer (37°C, 300 rpm) for 90 min. Cells were pipetted 
up and down every 10 min. Before centrifugation (300G, 5 min, RT) tubes were filled with 
CM-medium to deactivate the enzyme. Depending on the number of beating areas, 220-420 µl 
of CM-medium was added to the tubes, cell pellet gently re-suspended and cells counted, if 
there was enough cell material.  
         7.3.2 TMRM-labeling for cardiomyocytes 
Cells in the plates containing the beating clusters were labeled with Tetramethylrhodamine 
methyl ester perchlorate (TMRM) (Invitrogen, Eugene, OR, USA; cat. T-668). This is a 
fluorescent dye that labels mitochondria and because of cardiomyocytes’ high mitochondrial 
content, compared to many other cell types, this staining could be used as a tool for sorting 
cardiomyocytes from other cells (Hattori et al. 2010). Concentrations of 20 nM, 50 nM and 
100 nM were used on different plates (total of 3 wells; no replicate samples). TMRM was 
pipetted straight to the plates containing beating areas and incubated in the cell incubator for 2 
hours. Medium was changed and plates were examined immediately with fluorescence 
microscope (Olympus IX-71 MT_10D Fluorescence microscope (Soft imagining solutions 
gmbh, D82152, Planegg Germany). In the second experiment we used 10 nM concentration of 
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TMRM and the dye was left in the wells (total of 2 wells) for 4 hours, and the images were 
taken 3 hours after the dye was removed. 
   7.4 Protein labelling 
After counting, the desired amount of cells was re-plated onto glass bottom dishes (MatTek 
Corporation, Glass Bottom Dishes no 1.5, Ashland, OR, USA; cat. P35G-1.5-7-C, diameter 
0.7 cm) which were coated with mouse laminin (1 mg/ml) (Sigma Aldrich; cat. L2020-1MG). 
Before coating, laminin was diluted with PBS (12 µl/400 µl). A hundred µl of the solution 
was then pipetted on each glass bottom dish and incubated for at least 1 hour in the dark (RT). 
After removing laminin, the dishes were washed with sterile PBS before adding 100 µl of cell 
suspension containing the desired number of cells. Dishes were then incubated in cell 
incubator for 3 hours to let the cells attach to the bottom. Then 2 ml CM-medium was added 
to each dish. Medium was changed every second day and cells were cultured for at least 5 
days before fixing. 
For protein labelling the medium was removed and cells were fixed with 4% 
paraformaldehyde (PFA, J.T. Baker, Deventer, Holland; cat. 1157) for 20 min in room 
temperature. Dishes were washed twice with PBS. Cells were then permeabilized with 0.2% 
Triton X-100 in PBS (Triton X-100, Sigma Aldrich; cat. T8787, USA) at RT for 1 hour. After 
that, cells were incubated in blocking buffer which contained 5% normal goat serum 
(Chemicon International, Temecula, CA, USA; cat. S26-LITER) in PBS at RT for 1 hour to 
block unspecific binding sites. Primary antibodies were then diluted and added to the dishes.  
We used antibodies for two different proteins expressed in cardiomyocytes; myosin heavy 
chain (MHC; Upstate Temecula, Antimyosin Heavy Chain mouse monoclonal antibody, 
Clone A4.1025, Temecula, CA, USA; cat. 05-716) diluted 1:400 in blocking buffer and Nkx2 
(mouse monoclonal antibody to Nkx2.5 [2E1], AbCam, Cambridge, UK; cat. ab91196) 
diluted 1:1000 in blocking buffer. MHC staining was done to 4 differentiation batches (Figure 
1). One plate containing non-beating cells (replicate sample from UEFhfiPS 1.4 CM-diff. 2) 
was immunolabelled with Nkx2.5 antibody to find out if it could be used as a marker for 
cardiomyocytes. Dishes were incubated at 4°C overnight. Next day dishes were washed with 
PBS for 4 times 10 minutes. Secondary antibody, Alexa Fluor® 488 Goat Anti-mouse IgG (H 
+ L) (Invitrogen, Eugene, OR, USA; cat. A11001) 1:300 in blocking buffer was added to 
MHC immunolabelled dishes. Alexa Fluor® 568 Goat Anti-mouse (Invitrogen, Eugene, OR, 
USA; cat. A11004) was added to Nkx2.5 immunolabelled dishes. Dishes were incubated in 
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RT, in the dark for 1 hour and washed 4 times for 10 minutes with PBS. For MHC 
immunolabelled dishes, the second wash after secondary antibody contained 1:1000 dilution 
of DAPI nucleic acid stain (14.3 µM; Invitrogen, Eugene, OR, USA; cat. D1306). After the 
washes, PBS was added to the dishes and images were taken. 
Actin staining was done to one batch of stem cell derived cardiomyocytes (UEFhfiPS 1.4., 
CM-differentiation batch 0). Fixed cells were permeabilized with 0.5% Triton-X in PBS for 
10 min. Dishes were washed twice with PBS before dye solution was added. Phalloidin 
(Invitrogen, Eugene, OR, USA; cat. A12379) solution was mixed with 188 µl PBS and 2 µl 
FBS and pipetted onto the cells. Two units of phalloidin were used on each dish. Cells were 
incubated for 20 minutes in RT and dishes were washed twice with PBS. Images were taken 
with Olympus IX-71 MT_10D Fluorecence microscope (Soft imagining solutions gmbh, 
D82152, Planegg, Germany). 
   7.5 qRT-PCR 
Because of the low number of beating areas produced by some batches, cells were not always 
counted and plated on glass bottom dishes, as cells were also needed for RT-PCR. Also if the 
cell clusters did not dissociate, only RT-PCR was done. Quantitative real time reverse-
transcription-polymerase chain reaction was performed for microdissected, cardiomyocyte 
containing samples from five differentiation batches (figure 1). RNA isolation and cDNA 
synthesis were done with TaqMan® Gene Expression Cells-to-CT™ kit (Ambion Inc, the 
RNA Company, AM1729, Foster City, CA, USA). If a single cell suspension was not 
achieved, cells were not counted. If counting was possible, a sample of 30 000 cells was taken 
from the beating cells and from each of the two replicate samples of non-beating cells. Cells 
were centrifuged (7500 rpm, 5 minutes) and supernatant was removed. Cells were re-
suspended in 5 µl of cold PBS. Fifty µl of Lysis Solution containing 0.5 µl of DNase I was 
added to each sample. Lysis reaction was started with mixing the solution by pipetting up and 
down for 5 times and reactions were incubated for 5 min at RT. After this 5 µl of Stop 
Solution was added to each sample and mixed by pipetting up and down for 5 times, and 
samples were incubated for 2 min at RT. The samples were stored at -70°C until cDNA 
synthesis. For reverse transcription, reverse transcription master mix solution containing 25 µl 
of 2xRT buffer 2.5 µl of 20xRT Enzyme Mix and 12.5 µl Nuclease Free Water (DEPC 
Water) was prepared for each sample. RT Master Mix (40 µl) and 10 µl of the sample were 
mixed gently and centrifuged to the bottom of the tube. Reactions were first incubated at 37°C 
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for 1 hour for the reverse transcription reaction and then at 95°C for 5 min to inactive the RT 
enzyme. cDNA samples were stored at -70°C until the RT-PCR. 
PCR cocktail containing 10 µl of TaqMan® Gene Expression Master Mix (2x), 1 µl of 
TaqMan® Gene Expression Assay (20x) (Table 7) and 5 µl of Nuclease-free Water per 
reaction was prepared. Sixteen micro-litres of PCR cocktail and 4 µl of cDNA sample were 
then distributed into the wells of real-time PCR plate (MicroAmp® Applied Biosystems, Fast 
Optical 96-well Reaction Plate With Barcode (0.1 ml) (4346906, Singapore)) at RT. 
Reactions were done as duplicates. As a negative control, water was added to the reaction 
instead of cDNA. Plate was covered with optical adhesive film (MicroAmp™ Applied 
Biosystems, USA) and centrifuged (900xG) for one minute to remove air bubbles and collect 
the contents to the bottom of the wells. PCR was run in a real-time PCR instrument using 
following cycling conditions: 1 cycle + 50°C, 2 minutes; 1 cycle +95°C, 10 minutes; 40 
cycles +95°C, 15 seconds, +60°C, 1 minute. Results were normalized to the expression level 
of reference gene GADPH. Genes analyzed in RT-PCR are presented in table 7. 
Table 7. Genes analyzed in RT-PCR. All the expression assays were from Applied Biosystems® (product 
numbers in parentheses). 
Myl 2 (Myosin Light Chain 2) (Hs00166405_m1, 948647 B3) 
Nkx2.5 (NK2 transcription factor related locus 5) (Hs00231763_m1, 975424 B8) 
ANF (Atrial natriuretic factor) (Hs00383230_g1, 971421 C) 
GATA4 (Cardiac zinc-finger transcription factor) (Hs00171403_m1, 954561 A7) 
GADPH (Glyseraldehyde 3-phosphate dehydrogenase) (Probe dye: VIC-MGB, 
4326317E-1010038) 
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8 RESULTS 
   8.1 Production of cardiomyocytes from different PSC lines 
Results for each batch are shown in table 9. All used cell lines were cultured in their 
undifferentiated state on human feeder cells and passaged on Matrigel® before moving onto 
low attachment dishes for EB formation. When using dispase to help to detach the cells from 
Matrigel®, it was noticed that hESCs needed shorter incubation time (4 min) as hiPSCs (6-7 
min), indicating that hiPSCs are more tightly attached to the plates during culturing. 
UEFhfiPS 1.4 produced notably more undifferentiated colonies on Matrigel® than embryonic 
stem cell lines, thus providing more cells for further differentiation. Hence, the number of 
embryoid bodies was also greater in all UEFhfiPS 1.4 batches. Almost all differentiation 
batches were able to produce enough EBs for 40 wells (6-8 EBs/well), except two HS346 cell 
line batches (Table 8). 
Table 8. The number of wells the EBs were plated on in each differentiation batch. 
CM differentiation batch Number of wells 
UEFhfiPS 1.4. diff. 0 64 
UEFhfiPS 1.4. diff. 2 40 
UEFhfiPS 1.4. diff. 4 40 
UEFhfiPS 1.4. diff. 6 40 
HS181 diff. 1 40 
HS346 diff. 3 40 
HS346 diff. 5 12 
HS346 diff. 7 12 
 
UEFhfiPS 1.4 -line produced more beating clusters and the beating also started earlier 
compared to embryonic stem cell lines HS346 and HS181. On average, first contracting areas 
appeared on UEFhfiPS 1.4 cell line on day 14 after passaging the cells onto low attachment 
dishes. Each UEFhfiPS 1.4 batch produced 16 beating areas on average (n=4), the number of 
contracting areas per well varying from 0.313 – 0.425 (Table 9). On HS346 –cell line, first 
contracting areas were seen on average on day 20, resulting with total of 2.5 beating areas per 
batch (n=3), number of contracting areas per well being between 0.083 – 0.100. One batch of 
HS346 did not produce beating clusters at all. HS181 cell line was used only in one 
differentiation batch. Contracting areas varied in shape and size, and were usually seen on 
only few wells on each batch. Also the beating rate varied between the contracting areas. 
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Table 9. Occurrence and number of beating areas with different cardiomyocyte differentiation batches 
and cell lines. 
+Cell number indicates the number of cells acquired from the beating areas after dissociation.  
The size of the EBs has been a subject for studies and different methods have been developed 
to produce certain sized EBs to gain more efficient differentiation (Ng et al. 2005, 
Khademhosseini et al. 2006, Mohr et al. 2006, Burridge et al. 2007, Ungrin et al. 2008). We 
selected different sized EBs and pipetted the biggest and the smallest EBs generated on 96-
well plate: 24 larger and 24 smaller EBs, one per each well. This was done with 2 
differentiation batches; HS181 CM-diff.1 and UEFhfiPS 1.4 CM-diff. 2. It was seen that only 
the larger EBs attached to the bottom of the well resulting in cell growth, and beating areas 
occurred only in few of these wells. All the small EBs disintegrated a few days after plating. 
EB size varies a lot with our method because they are formed from different sized cell 
clusters, as the size is not controlled when undifferentiated cells are moved to ULA-plate 
from Matrigel. Also, it came clear that only EBs with distinct perimeter should be chosen for 
further differentiation as EBs that did not have sharp perimeter disintegrated soon after 
plating and did not result in cell growth. 
 
 
 
 
 
Differentiation batch and cell line 
 
The occurrence of first 
contracting areas (days from the 
beginning of the differentiation) 
 
 
No of beating 
areas 
Total number of 
cells (in beating 
areas)+ 
 
No of 
beating 
areas / well 
UEFhfiPS 1.4. Cm-diff. 0 15 ~20 ~60 000 0.313 
UEFhfiPS 1.4 Cm-diff.2  14 13 181 000 0.325 
UEFhfiPS 1.4 Cm-diff.4  14 16 121 000 0.400 
UEFhfiPS 1.4 Cm-diff.6 12 17 95 000 0.425 
HS181 Cm-diff.1  16 6 not counted 0.150 
HS346 Cm-diff.3  18 4 not counted 0.100 
HS346 Cm-diff.5  21 1 33 000 0.083 
HS346 Cm-diff.7  never - none 0.000 
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   8.2 Cardiomyocyte purification 
Contracting areas were micro dissected as carefully as possible with injection needles. The 
size and shape of the beating clusters varied greatly between all batches and cell lines and 
even within the batches. We tried accutase, TrypLE™ express and collagenase-pancreatin 
solutions for dissociating the beating clusters to single cell suspension but the only method 
that resulted in viable cells in single cell suspension was digestion with collagenase-
pancreatin solution. 
Number of cells from microdissected, beating clusters in UEFhfiPS 1.4 batches 2, 4 and 6 
varied from 95 000 to 180 000 cells per batch and on average one microdissected beating 
cluster contained 5600 to 14 000 cells (Table 9). UEFhfiPS 1.4 batch 0 produced over 20 
contracting areas of which the last 10 had about 60 000 cells (only the last ones’ cells were 
counted). A few clusters had not dissociated fully so the cell number is not exact. The only 
batch from HS346 used in re-plating produced one big beating cluster with 33 000 cells. First 
times we plated 50 000 cells per glass bottom dish. These dishes became confluent in few 
days and beating cells were seen on all plates. Due to previous and because of the fact that 
low numbers of beating clusters formed in some batches, we decided to try plating fewer 
cells. We plated 10 000 and 20 000 cells per dish with UEFhfiPS 1.4 differentiation batch 6 
and with HS346 differentiation batch 5, we plated 16 500 cells on two dishes. Cells attached 
to the bottom, but it took more time with fewer cells for the dishes to become confluent. All 
dishes contained beating cells after re-plating, but examining the dishes after immunostaining 
was easier with 20 000 cells or more, as the cells are more close to each other.  
TMRM (tetramethylrhodamine methyl ester perchlorate) is a fluorescent dye that reversibly 
labels active mitochondria (Hattori et al. 2010). First, we tested three different concentrations 
of TMRM on three wells of 4 well plate containing beating clusters from UEFhfiPS 1.4 CM-
differantiation batch 0 to see if the dye accumulates on contracting cells because of the high 
number of mitochondria. Concentrations were 20 nM, 50 nM and 100 nM, each concentration 
on one well. TMRM was pipetted straight on wells and incubated in cell incubator for 2 
hours. Medium was changed and plates were examined immediately with Olympus IX-71 
MT_10D Fluorescence microscope (Soft imagining solutions gmbh, D82152, Planegg 
Germany). With all three concentrations, thick layers of cells were stained better than the 
beating clusters making them disappear to the background. This was probably due to high 
concentrations and the absence of washout time before taking the images. After waiting for 
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few hours and re-examining the plates, TMRM had started disappearing from the background, 
making the beating areas more clearly visible but not as detectable from the other cell material 
as wanted. Next we used 10 nM of TMRM that was pipetted on two wells containing beating 
clusters from the UEFhfiPS 1.4 CM-differantiation batch 0. Plates were incubated for 4 hours 
after which they were examined 3 hours after medium change. This time beating areas were 
clearly distinguishable from surrounding cells and still beating (Figure 3). 
 
Figure 3. TMRM-staining of beating clusters. Samples were incubated with 10 nM of TMRM for 4 hours, 
medium was changed and samples were examined 3 hours thereafter. On the left, light microscope image and on 
the right, fluorescence image from the same area showing the red fluorescence of TMRM. In the left image the 
contracting area is highlighted with black line. 
Some of the thick cell layers on the edges of tissue were also stained red (Figure 3). However, 
as TMRM is intended to be used in sorting of cardiomyocytes from other cells in single cell 
suspension, this should not be a problem. TMRM did not seem to have any harmful effect on 
the cells in our study either as beating clusters continued contracting normally until they were 
discarded.  
   8.3 Protein labelling 
Actin is a marker of embryonic myocardial cells expressed at various stages of embryonic 
heart development, but it is also found in adults (Clément et al. 2007). We only did one actin 
staining for one batch (UEFhfiPS 1.4 CM-differentiation batch 0) because actin did not 
appear to be cardiomyocyte specific, as it stained all the cells on the plate (Figure 4; images 
were taken with Olympus IX-71 MT_10D Fluorescence microscope). For more specific 
results, myosin heavy chain staining was used from there on.  
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Figure 4. Actin staining of re-plated cardiomyocytes. On the left, actin staining (green). On the right, the same 
as a phase-contrast image 
 
Myosin heavy chain staining was not made to all batches as a single cell suspension was 
required for re-plating and embryonic stem cell lines did not produce enough beating cells for 
all demanded studies. Myosin heavy chain immunostaining exhibited very distinguished 
myosin patterns in cells and together with the rhythmic spontaneous contracting activity, it 
can be concluded that all these stem cell derived beating cells were cardiomyocytes (Figure 
5). Compared to the same staining made for dishes containing non-beating cell material from 
the same wells, the difference is distinct and it shows that enrichment of cardiomyocytes was 
successful. Only one staining was made with Nkx2.5 because it did not seem to be 
cardiomyocyte specific as it stained the nuclei of all cells present in the sample (data not 
shown). 
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Figure 5. Myosin Heavy Chain staining. MHC immunostaining (green) and nuclear staining with DAPI (blue). 
A: UEFhfiPS 1.4 Cm-diff. 4, B: UEFhfiPS 1.4 Cm-diff.2, C: UEFhfiPS 1.4 Cm-diff.2 D: HS346 Cm-diff. 5, E-
F: Non-beating cell material from HS346 Cm-diff.5 (E) and UEFhfiPS 1.4 Cm-diff.4 (F). Images were taken 
with Olympus Fluoview 1000 confocal microscope. 
   8.4 qRT-PCR 
qRT-PCR was made for five batches of cells (Figure 1), results are shown in figure 6. If a 
single cell suspension was achieved, a sample of 30 000 cells was taken from the beating cells 
and from each of the two replicate samples of non-beating cells. Replicate samples were not 
done, because of the small amount of cells. With HS346 and HS181 batches cells were not 
counted as single cell suspension was not achieved. 
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Figure 6. Gene expression in cells from microdissected beating clusters. RT-PCR results presented as fold 
change compared to the non-beating cell material from each batch. Notice the logarithmic scale. Nkx2.5; NK2 
transcription factor related locus 5, ANF; atrial natriuretic factor, GATA4; cardiac zinc-finger transcription 
factor. 
 
Results show that the expression of cardiac genes is elevated in every batch compared to the 
non-beating cell samples, which supports the other results indicating that the derived beating 
cells were cardiomyocytes, and that it is possible to enrich cardiac cells by using micro 
dissection. MYL2 fold change could not be determined because gene was not detected in non-
beating cell material, but it was present in the cardiomyocyte samples, although the 
expression was barely detectable with RT-PCR. 
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9 DISCUSSION 
The ability to generate functional cardiomyocytes from hPSCs has been a big breakthrough, 
but there are still problems that have to be overcome before these cells can be used in 
regenerative cardiovascular medicine. Using hESC in the differentiation has its ethical 
concerns that can be avoided by using hiPSCs, but this requires the development of better 
hiPSCs deriving techniques. The protocols for the differentiation have become more and more 
refined and efficient, but there still is not a protocol that results in 100 % of cardiomyocytes. 
By combining different protocols and optimizing over 45 variables in the differentiation 
process, Burridge et al. (2011) have been able to develop a cardiac differentiation system that 
was highly efficient (94.7±2.4%) in the tested four hESC and seven hiPSC lines. This is a 
promising result, especially as the efficiency of the protocol is usually highly cell line 
dependent and same protocols do not always work in a similar manner with individual hESC 
and hiPSC lines. 
In our study UEFhiPSC1.4 cell line produced clearly more cardiomyocytes than HS346 or 
HS181 and in addition, it was not as sensitive to the processing during differentiation as the 
embryonic stem cell lines. HS346 cell line was chosen for the study because the lab of Prof. 
Outi Hovatta had got good results in cardiomyocyte differentiation with this particular cell 
line in Karolinska Institutet, Stockholm, Sweden. Reason why the HS346 cell line did not 
produce cardiomyocytes as well as it had in previous studies might be due to various reasons, 
for example differences in used protocols. Also, HS346 did not produce as much 
undifferentiated colonies as the iPSC line, partially explaining the variations in the 
differentiation efficiency, as there was less cell material to start the differentiation with. This 
difference in initial amount of cells for differentiation might partially explain why UEFhfiPS 
1.4 produced significantly more beating clusters than either of the embryonic stem cell lines, 
as the larger amount of embryoid bodies made it possible to pick the best looking ones for the 
differentiation. 
Studies have shown that differentiation to cardiac fate can be enhanced by controlling the EB 
size (Ng et al. 2005, Khademhosseini et al. 2006, Mohr et al. 2006, Burridge et al. 2007). In 
these studies the optimal size for the EBs varies between 100 to 300 µm depending on the 
used method. We also noticed that the size of EBs affects the success of cell growth and 
cardiomyocyte differentiation. In our study, we did not measure the sizes of the spontaneously 
formed EBs but selected visibly the biggest and smallest EBs and plated them to a U-shaped 
54 
 
96-well plate. We chose U-shaped well to limit the cell growth into a small area, and to 
simplify monitoring their growth and possible occurrence of contracting areas. Only the 
biggest ones resulted in some cell growth when smallest ones disintegrated. The smallest EBs 
might have contained already dead cell material, explaining the unsuccessful cell growth. In 
spite of successful cell growth seen with the biggest EBs, beating clusters only appeared on 
few of the wells. This might be due to inadequate cell to cell interactions that are assumed to 
partially guide the differentiation towards cardiac fate (Goh et al. 2005, Vidarsson et al. 2010, 
Rajala et al. 2011). When several EBs were plated on the 4-well plates, the larger amount of 
cell material might help the cells of mesoderm to differentiate towards cardiac fate. The 
importance of endoderm in the induction of mesoderm has been studied, and this might be 
one reason why differentiation was better when plating more EBs to each well (Filipczyk et 
al. 2007, Shiba et al. 2009, Dambrot et al. 2011, Mummery et al. 2012). Because of the low 
amount of contracting areas, 96-well plates are probably not good for spontaneous EB 
method, but would need guided differentiation protocol and controlled EB size to enhance the 
differentiation. 
When selecting EBs for further differentiation, we noticed that not all the EBs had distinct, 
clear outlines. To see, if it had any effect on further cell growth, we pipetted them to few 
separate wells. After a few days of culturing, all these EBs had disintegrated and did not result 
in cell growth. As EB formation resembles the early stages of embryonic development, EBs 
have outer layer of primitive endoderm surrounding undifferentiated cells and primitive 
ectoderm (Norström et al. 2006). These imprecise perimeters of the EBs might thus indicate 
that they are not fully formed EBs or have dead cells on the outer layer which could explain 
why they did not grow after plating. Because of all the issues discussed above, EB method is 
not very reproducible method for cardiomyocyte differentiation. 
Even if the protocols produce cardiomyocytes with high efficiency, it is important to develop 
purification methods that enable the generation of pure cardiomyocyte populations. This is 
very important if hESC/hiPSC derived cardiomyocytes are going to be used in regenerative 
medicine, where other cell types inside cardiac grafts could cause serious problems. Also 
strategies that enable the production of high purity cardiomyocyte populations without genetic 
modification is important, as it might also cause problems, e.g. mutations. The purification of 
the beating clusters turned out to be quite challenging. The clusters had to be dissociated into 
single cells because studies have shown that they are not purely cardiomyocytes but also 
contain cells from all three germ layers (Kehat et al. 2001). Achieving single cell suspension 
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is thus important for generating pure cardiomyocyte preparations, and also many of the 
characterization methods require it. 
Cardiomyocytes form junctions with each other that let the action potential move from cell to 
cell, making them tightly bound to each other (Dhein and Jongsma 2004). This makes the 
separation of cells in beating clusters challenging as the generated cardiomyocytes should stay 
viable and beating also as single cells. Dissociating the clusters of cells is important as the 
contracting areas contain also other cell types in addition to cardiomyocytes. It is also 
important to get single cardiomyocytes for further analysis and single-cell studies. We tried 
three different compounds and collagenase-pancreatin solution succeeded in this. After 
dissociating the clusters, examination of the re-plated cells showed clearly that there were lots 
of other cell types present in the samples in addition to cardiomyocytes. Successfully 
separated cardiomyocytes started beating after re-plating and confocal Ca
2+
 imagining was 
done to few single cells. These beating cells had Ca
2+
 transients typical for cardiomyocytes 
(data not shown). The results suggest that collagenase-pancreatin solution is a safe way to 
dissociate beating clusters as the cells continued to contract also as single cells after re-
plating. Majority of the re-plated cells were non-beating, hence for efficient enrichment, 
cardiomyocytes need to be sorted from the other cells before re-plating in a way that does not 
affect the viability of the cells. 
The study with TMRM for cardiomyocyte separation purpose was very encouraging, as the 
dye clearly accumulated into the beating areas, like Hattori et al. 2010 had demonstrated 
before. Some of the thick layers of cells were also stained, but this will not be a problem in 
further studies as TMRM is supposed to be used in single cells only. As in previous studies 
(Hattori et al. 2010), staining did not affect the cell viability even with the higher 
concentrations and the beating clusters continued to contract during the staining and after the 
dye had vanished. Therefore, this method enables cardiomyocytes separated with 
fluorescence-activated cell sorter (FACS) to be re-plated after sorting to derive cardiomyocyte 
populations with higher purity. Our preliminary results are encouraging as the staining 
procedure seemed to work well. 
The expression of cardiac genes was determined with RT-PCR. Nkx2.5 is one of the earliest 
transcription factors and is activated shortly after the heart fields are formed, having also a 
role in the activation of cardiac structural genes such as MLC and MHC (Filipczyk et al. 
2007, Mummery et al. 2012). GATA4 is essential in the formation of heart tube and later in 
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the formation of proepicardium and muscle development, and is also one of the activating 
factors for cardiac structural genes (Filipczyk et al. 2007, Mummery et al. 2012). ANF is a 
hormone expressed in atrial and ventricular cardiomyocytes. The expression of the studied 
genes was elevated in all of the cardiomyocyte samples compared to the non-cardiac samples. 
MYL-2 (MLC2) was not present in the non-cardiomyocyte RT-PCR samples so the fold 
change could not be determined, although low expressions were seen on cardiomyocyte 
samples. The differences in the presence of cardiac genes between different batches as well as 
between cardiomyocyte and control samples is probably due to the random selection of 
control material, making it possible that some of the control samples might contain cardiac 
cells which increases the amount of cardiac genes in the sample. Also the samples from 
contracting clusters can contain other cell material in addition to cardiomyocytes. The 
differences in the gene expression between the batches can also mean that there are different 
cardiac cell types in different maturation stages present in the samples. Our results indicate 
that GATA4, Nkx2.5 and ANF are all useful markers when estimating the success of the 
cardiac differentiation and enrichment methods used. 
In addition to RT-PCR, immunostaining with MHC was made to ensure the presence of 
contractile elements. MHC staining showed clear sarcomeric structures, further indicating that 
the beating cells were cardiomyocytes. All of the results together show that spontaneous EB 
method can be used to create functional cardiomyocytes for small scale studies. Micro 
dissection can be used as an enrichment method, but it is not very reproducible, as the results 
are highly dependent of the person who performs it. The whole protocol was time consuming, 
the efficiency varied between batches and cell lines and generated amount of cardiomyocytes 
was small, but it was enough for single cell studies. The efficiency of the method we used 
could be increased by adding of small molecules/growth factors and using defined sized EBs. 
Also the selection with TMRM and FACS before replating would increase the purity of the 
resulting preparations, making it easier to study the cells further.  
Even if the used method can produce cardiomyocytes efficiently, and purification methods 
succeed in making pure cardiomyocyte populations, the degree of maturation presents another 
problem. As mentioned before, it has been noted that hESC/hiPSC derived cardiomyoctes 
resemble more of the fetal stage cardiomyocytes than mature ones (Filipczyk et al. 2007, 
Narsinh et al. 2011, Rajala et al. 2011). This is a problem as their functional properties differ 
as well, making it a safety issue when the goal is in regenerative medicine (Filipczyk et al. 
2007, Vidarsson et al. 2010, Narsinh et al. 2011, Rajala et al. 2011). Strategies for generating 
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more mature cardiomyocytes have to be developed, but the generated cardiomyocytes still 
provide a useful model for in vitro studies. 
Since the first report of stem cell derived cardiomyocytes, progress in this research field has 
been made all the time. But before these hESC/hiPSC derived cardiomyocytes can be used in 
regenerative medicine, many problems including safety issues have to be solved. Hopefully in 
the future, it is possible to generate pure and mature cardiomyocyte populations that can be 
used as a treatment for heart diseases resulting from myocardiac dysfunction as well as 
functional models for genetic myocardiac diseases. 
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